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Haemophilia A, haemophilia B and von Willebrand's disease are the three commonest 
inherited disorders of coagulation. Genetic counselling at the time this project was 
undertaken (1985/86) was hampered by the inability of coagulation tests to clearly 
distinguish carriers from non-carriers for the X-linked haemophilias and by the need for 
second trimester fetal blood sampling in those families who opted for prenatal diagnosis. 
The present project aimed to utilise the newly available gene probes for these three 
conditions to measure their clinical value for improved genetic counselling within 
affected families.
DNA was extracted from 216 individuals from 16 families affected by haemophilia A of 
whom 40 were affected males, 38 were obligate carrier females and 71 were females at 
risk. 4 restriction fragment length polymorphisms (RFLPs), two intragenic, exon 17- 
18/Bcl I (F8 A) and exon 26/Bgl I (F8 B), and two extragenic, DX13/Bgl II and Stl4/Taq 
I, were applied. Allele frequencies were 0.76/0.24 for F8 A, 0.81/0.19 for F8 B and 
0.625/0.375 for DX13. Allele frequencies were not calculated for St 14 which is a 
highly polymorphic system. There was no evidence of gross gene deletion. Two 
families studied had other X-linked disorders, one had G6 PD deficiency, the other red- 
green colour blindness. Linkage between these disorders, the factor VIII gene and the 
two extragenic probes was supported by results found. 29 of 71 females at risk (41%) 
could be offered definitive determination of carrier status from the result of intragenic 
RFLPs; a further 22 (31%) had refined genetic information from extragenic RFLPs. 
However with the probe Stl4, 3 recombinants were observed amongst 28 phase known 
meioses (10.7%) highlighting the risks associated in using information obtained from 
extragenic probes in genetic counselling.
DNA analysis was unhelpful for 20 females at risk (28%) either because of non- 
informative RFLPs or lack of samples from relatives. A further disadvantage of this 
technique which became apparent was that results depended upon fathers tested being 
true biological fathers.
24 females at risk who had earner status assessed by RFLP analysis had also had 
conventional coagulation testing to assign carrier status. 13 women were identified as 
non-carriers using DNA techniques and all 13 had coagulation factor assay results which 
would also have supported non-carrier status. 1 1  women were identified as earners, 8  
from intragenic RFLPs, 3 from extragenic. Only 6  of these 11 women would have been 
identified as earners from coagulation testing and the other 5 would have been given 
"odds" from 3:1 to 16:1 that they were not carriers. 5/24 (20.8%) women had
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coagulation tests results at variance with RFLP analysis suggesting that coagulation tests 
are a less accurate method of assigning carrier status.
During the study, one first trimester pre-natal diagnosis was undertaken using an 
intragenic RFLP. The fetus was shown to be a carrier female.
128 individuals from 12 families affected by haemophilia B were investigated of whom 
30 were obligate carrier females, 32 were possible carrier females and 31 were affected 
males. 3 intragenic RFLPs, factor 9(VIII)/Taq I, factor 9(VIII)/Xmn I and factor 
9(XIII)/Dde I were used. The allele frequencies identified were 0.63, 0.68 and 0.77 
respectively for each major allele. No gross gene deletions were identified. 22 of 32 
women (6 6 %) could be offered definitive assignment of carrier status from the results of 
RFLP data. 34% of women were unable to have earner status determined either due to 
non-informative RFLPs or lack of DNA from relatives. Since the probes used were all 
intragenic, the information obtained is clearly more reliable than coagulation data.
One pre-natal diagnosis performed during the study showed the fetus to be an unaffected 
male.
38 individuals from 11 families affected by von Willebrand's disease were tested with 
the RFLP pvW Fl 100/Bgl II. In 10 families, the disease was autosomal dominant and in 
1 family it was autosomal recessive. The observed allele frequency was 0.64 for the 
major 9kb allele. No evidence of gross gene deletion was observed. A new RFLP was 
identified in four individuals from 3 families (10.5% of individuals tested) which 
showed that a 13kb band, thought to be a constant band, was replaced by a band of 
15kb. Co-segregation observed in individuals tested was consistent with chromosome 
12 and the von Willebrand gene isolated being the disease locus. The DNA results 
obtained supported the hypothesis that the individual presenting with severe von 
Willebrand's disease was homozygous for an abnormality of the von Willebrand factor 
gene.
The study clearly showed in a large number of families the utility of DNA probes in 
these three common disorders of coagulation. The advantages and disadvantages are 
compared with other studies and the utility is compared to conventional approaches to 
carrier testing and pre-natal diagnosis which were available when the study was 
undertaken.
12
CHAPTER I ■ INTRODUCTION
Inherited coagulation disorders are all rare. However, for the affected individual they are 
lifelong, may be crippling and can affect all aspects of that individual's life. Treatment is 
expensive and has associated side effects. Particularly with X-linked conditions even 
unaffected female members of the family may be concerned that they carry the defective 
gene and can transmit it to their own children. Thus these disorders may cast a shadow 
over a whole family.
Clinicians managing affected patients see treatment as their immediate response to the 
problem but prevention as the ultimate goal. Increasing understanding of molecular 
genetics has opened the way to improved diagnostic and research methods. The studies 
described in this thesis use recently developed molecular techniques to investigate family 
members in families affected by haemophilia A, haemophilia B or von Willebrands 
disease with the main aim of allowing improved carrier detection and prenatal diagnosis
1.1 NORMAL HAEMOSTASIS
In 1964 two groups independently suggested that blood coagulation was achieved by a 
series of enzyme reactions which function as a biological amplifier. This they termed the 
"cascade" or "waterfall" hypothesis [Macfarlane, 1964; Davie and Ratnoff, 1964]. In 
the ensuing 25 years much more has been learnt about the individual clotting factors 
involved in this cascade, their interactions and the involvement of calcium and platelets 
but overall the hypothesis still stands.
The cascade is divided into two pathways, the intrinsic and the extrinsic, which have a 
common endpoint with the activation of factors X, V and II and ultimately the formation 
of fibrin. The intrinsic pathway is further divided into the initial contact activation 
system followed by activation of factor IX and the interaction between factors IXa, Villa 
and X (Fig 1).
The coagulation cascade is only part of a complicated haemostatic network. Primary 
haemostasis is achieved through the interaction of platelets and the damaged vessel wall. 
The initiation of coagulation also triggers off fibrinolytic pathways preventing 
widespread blood coagulation and limiting the coagulant response to a wounded area. 
There are also links between the haemostatic system and other body defence systems 
such as the complement system and the kinin generating system [Hutton, 1989].
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Figure 1.
Schematic representation of the intrinsic pathway o f coagulation. Acivated coagulation 
factors are represented by their Roman numerals. Activated coagulation factors are 
represented by their Roman numerals followed by a small case a . Other abbreviations : 
high molecular weight kininogen, HMK; calcium ions Ca++; phospholipid, PL
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As this thesis concentrates on abnormalities of factor IX and VIII, this part of the 
cascade will be described in further detail here.
Factor IX is a protein synthesised in the liver which is dependent upon the presence of 
Vitamin K to function properly. It is activated in a two step calcium-dependent 
mechanism through the enzyme activity of factor XIa. First an initial cleavage of the 
A rgl45 -Alal46 bond gives rise to a two chain molecule linked by disulphide bonds. 
This intermediate product has no detectable clotting activity but cleavage of the Argl80 - 
Vall81 bond results in the release of an active peptide (IXa) with a molecular weight of 
about 10,000 daltons [McGraw et al, 1985A]. IXa proceeds to activate factor X. This 
reaction will take place in the presence of IXa alone but the speed of the reaction is 
greatly increased in the presence of co-factors phospholipid, calcium and activated factor 
VIII [van Dieijen et al, 1981].
Sequencing of the gene for factor IX has shown it to consist of about 33.5kb of DNA 
which code for eight exons and seven introns [Yoshitake et al, 1985; Anson et al, 
1984]. The eight exons code for a pre-pro-leader sequence and 415 amino acids which 
make up the mature protein. The exons have been numbered a to h. The first exon 
consists of a leader sequence and the signal for initiation. Translation begins with the 
code for a Met residue which is 46 bases before the codon for the amino terminus of the 
mature protein. The pre-pro sequence code for a hydrophobic portion and two cysteine 
residues are contributed by the first exon. This is followed by a hydrophilic portion 
coded for by part of the second exon. The first and second exons are separated by an 
intron of about 6 kb whereas the second and third have only short intervening sequences. 
The remainder of the second and third exon code for the domain of factor IX which 
contains its gamma carboxyglutamic acid (GLA) residues which contribute the calcium 
binding sites. Exons four and five are separated by a large intron and each codes for a 
region of the protein which is homologous to epidermal growth factor. The sixth exon 
codes for the two activation cleavage sites with flanking sequences. The last two exons 
occur at the end of the genomic sequence, separated by a short intervening sequence. 
Together they code for the balance of the heavy chain of factor IXa which shares 
considerable homology with other serine proteases [Thompson, 1986].
Factor VIII is a single chain protein. Its main site of synthesis is uncertain but is 
believed to be the hepatic sinusoids. It circulates in close association with the von 
Willebrand factor molecule. In the presence of small amounts of thrombin, proteolysis 
of factor VIII produces an activated form of the molecule, factor Villa. Larger amounts 
of thrombin destroy factor VIII activity [Bloom et al, 1985]. Activated factor VIII is not 
itself an enzyme but acts as a co-factor. It potentiates the activation of factor X by
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aligning factor IXa and factor X on the phospholipid platelet surface to promote an 
efficient interaction between the trio [van Dieijen et al, 1983].
The factor VIII gene was cloned and sequenced in 1984. The entire gene is 186 
kilobases of DNA which is estimated to be 0.1% of the human X chromosome, and it 
consists of 26 exons and 25 introns. The coding DNA is only 9 kilobases long and 
codes for 2351 amino acids of which the first 19 comprise the secretory leader peptide. 
Computer analysis of factor VIII protein sequence has revealed three homologous 
sequences (the A domain). The second and third domain are separated by a B domain of 
983 amino acids which is cleaved off during activation. After the third A domain, there 
are 2 C domains of 150 amino acids which have about 40% homology with each other 
[Gitschier et al, 1984; Toole et al, 1984; Wood et al, 1984; Vehar et al, 1984].
Von Willebrand factor (vWF) is a protein active in primary haemostasis, mediating 
platelet adhesion via the platelet membrane glycoprotein lb to the subendothelium at sites 
of vascular injury. vWF also binds to the platelet membrane Ilb/IIIa complex and may 
help to stabilise the initial platelet aggregate. The endothelial cell is the principal site of 
synthesis of vWF. The vWF molecule is synthesised initially as a 260k precursor called 
pre-vWF. Before release into the circulation, it undergoes post-translational 
modification to form dimers in which the sub-unit has a molecular weight of 2 2 0 k. 
These dimers are packaged into an array of multimers with molecular weights ranging up 
to 10^k. The multimeric form of vWF is the form which is active in primary 
haemostasis. It is also the form which binds non-covalently with factor VIII in the 
circulation, protecting it from non-specific proteolysis [Mackie and Bull, 1989].
The cDNA for human vWF has been isolated and mapped to chromosome 12 by in-situ 
hybridisation [Ginsburg et al, 1985; Lynch et al, 1985; Sadler et al, 1985; Verweij et 
al, 1985A]. The gene for human vWF is approximately 178kb long. It consists of 58 
exons and 51 introns. The fact that this is a long gene may increase the opportunity for 
polymorphism and explain the relatively high frequency of autosomal dominant vWD 
[Mancuso et al, 1989]. The full length cDNA construct includes a coding sequence of 
8439 nucleotides which encode a single chain precursor of 2813 amino acid residues 
representing a putative signal peptide, a pro-sequence and mature vWF of 22, 741 and 
2050 amino acids respectively. The pro-sequence is released into the circulation cleaved 
from the vWF molecule and has been referred to as vW Agll [Shelton-Inloes et al, 
1987A]. It is hypothesised that dimerization of vWF occurs via disulphide bonding of 
the C terminal region and that polymerisation occurs when the pro-vWF specific 
sequences are removed, revealing reactive disulphides which can then participate in 
interdimer polymerisation.
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About 90% of the precursor vWF protein is constructed of repetitive regions, indicating 
that the precursor vWF gene has evolved from a series of duplicative events of at least 
four different regions. The precursor consists of two duplicated (B,C), a triplicated (A), 
a quadruplicated (D) and a partly duplicated domain D' in the following order:
H - Di - D2  - D' - D3 - Ai - A2  - A3 - D4  - Bi - B2  - C i - C2  - OH [Verweij et al, 1986].
Sequencing and RNA mapping analysis of the 5’ non-coding region of the vWF gene 
have revealed the site of transcription initiation and of two structures, known as 
"CCA AT boxes", which play a regulatory role in transcription. One of these CCA AT 
boxes lies in an unusual position, downstream of the transcription initiation site. This 
has also been described in the prolactin and a -1  antitrypsin gene. All these genes 
encode secreted proteins that are synthesised by a limited repertoire of cells [Collins et al, 
1987]. Whether the unusual position of the CCA AT box is related to this fact and in 
some way promotes the production of a secretory protein is as yet uncertain. Specific 
proteolytic fragments of vWF have been found to bind to platelet glycoprotein lb, 
glycoprotein lib, Ilia and collagen [Girma et al, 1986].
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1.2 MOLECULAR BIOLOGY
I.2i From DNA to Protein
Clinical geneticists from Mendel onwards defined genes as the biological units of 
heredity and proved that they are aligned linearly on the chromosomes. Subsequently it 
was shown that genes control the structures of protein and it is now known that genes 
consist of DNA or deoxyribonucleic acid. DNA is a double-stranded molecule made up 
of chains of sugar-phosphate molecules attached to one of four nucleotide bases: 
adenine (A), thymine (T), guanine (G), and cytosine (C). The two strands are held 
together in a double helical structure, linked by hydrogen bonds, by complementary base 
pairing whereby an A molecule is always paired with a T molecule and C with G. This 
specific base pair complementarity is fundamental to many of the particular properties of 
DNA and to many of the laboratory techniques used in molecular biology.
DNA is essential for protein synthesis. Genetic information is encoded by the sequence 
of the bases; it is a triplet non-overlapping code in which three bases determine a 
particular amino acid. DNA replication involves the copying of a pre-existing DNA 
strand to produce a complementary sequence; a copy of this sequence will then produce 
the original (or template) sequence. In the replication of DNA both strands are copied. 
DNA can also be copied to make the messenger molecule ribonucleic acid or mRNA in a 
process called transcription. mRNA is similar to DNA but the sugar involved is ribose 
rather than deoxyribose and thymine is replaced by uracil. Transcription of mRNA from 
DNA is the first step in protein synthesis and is brought about in the nucleus by an 
enzyme called RNA polymerase II. It starts on a specific triplet (ATG) or initiator region 
and stops at a termination triplet (TAA, TAG or TGA). The initial RNA strand produced 
is long and biologically inactive. The coding sequences or exons are interrupted by non­
coding intervening sequences or introns. Processing of mRNA involves excision of 
introns and splicing of exons. It is chemically modified at its 5' end by the addition of a 
so-called CAP structure, and at its 3' end by the attachment of a long string of adenylic 
acid residues (poly A). mRNA then moves into the cytoplasm where translation from 
RNA to protein takes place on polysomes, groups of ribosomes which themselves are 
structural units consisting of ribosomal RNA and protein. The triplets of nucleotides 
coding for an amino acid are recognised by a third type of RNA, transfer RNA or tRNA. 
There is a specific tRNA present in the cytoplasm for each amino acid. The sequence of 
the mRNA is 'read' from the 5' end to the 3' end and amino acids are attached 
sequentially and form peptide bonds between each amino acid until the whole message 
has been translated into a protein which is then released.
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Because the code for each amino acid is specific an alteration in one base of the DNA 
molecule may alter the protein produced. Similarly an abnormality at the initiator or 
terminator sequence may abolish RNA transcription. This is complicated by the fact that 
close to the coding gene on the DNA strand are areas known as promotors and 
enhancers. Abnormalities within this stretch of DNA may also affect RNA transcription. 
An omission of one base will affect all the subsequent triplets coding for amino acids and 
may result in an abnormal or very short protein molecule being produced which may be 
non-functional. Any alteration that affects the excision of introns and splicing of the 
RNA molecule may also cause abnormal proteins to be produced. Understanding the 
process of normal protein production helps to explain the molecular pathology involved 
in abnormal or dysfunctional protein production (Fig 2).
I - 2ii DNA Electrophoresis and Probing
In order to separate DNA electrophoretically it first has to be cut into smaller fragments. 
This is achieved using enzymes isolated from bacteria known as restriction enzymes. 
Each restriction enzyme will cleave DNA only through a given nucleotide sequence 
which it recognises. The smaller fragments of DNA produced by digestion of DNA with 
a restriction enzyme can be separated electrophoretically in an agarose gel. The DNA is 
transferred from the gel to nitrocellulose or nylon membrane by a process known as 
Southern blotting.
DNA probing relies upon the specific binding of complementary sequences of DNA. A 
DNA probe is simply a segment of DNA taken from, or close to, a gene of interest. The 
electrophoresed DNA can be rendered single stranded by exposures to an alkali solution. 
A DNA probe made single sttanded by boiling and radio-labelled with 32p wjq bind 
specifically to complementary DNA sequences. Non-specific binding can be washed 
off. The specifically bound probe is then visualised on an autoradiograph.
I.2iii Restriction Fragment Length Polymorphisms (RFLPs)
Throughout the human genome there are harmless mutations present, often in the form 
of single base substitutions, which do not affect DNA transcription. They may however 
alter a restriction enzyme site. These mutations are inherited and so an individual may 
have different patterns of restriction enzyme cutting in the two alleles of a gene which 
they have inherited. Different sizes of DNA fragment, known as restriction fragment 
lengths, will be detected on the autoradiograph. This is the phenomenon of restriction 
fragment length polymorphism. It is possible to use the different size of fragments to
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From DNA to Protein
Transcription from DNA to RNA in the cell nucleus followed by translation from RNA
to protein in the cytoplasm.




Diagram of typical autosomal RFLP. Both parents are heterozygous, one child is 
homozygous for the larger fragment A, one is homozygous for the smaller fragment a, 
and two children are heterozygous.
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track the inheritance of an allele throughout a family without needing to know the precise 
molecular abnormality of the disease in that family (Fig 3).
If the RFLP lies within a known gene then there will be a close correlation between the 
inheritance of an RFLP allele and an allele of the gene. This association is described as 
linkage. Linkage is very strong when the RFLP is intragenic but if the RFLP lies close 
to but outside the gene of interest there is a possibility of genetic cross-over at meiosis 
between the RFLP and the gene site resulting in loss of linkage or genetic recombination. 
Linkage of an RFLP to a gene of interest can be calculated by the number of 
recombinations observed between the two when a large number of families are studied 
and expressed as a recombination fraction, called 0  .
Much of the information derived from RFLP analysis depends upon studying families 
and family pedigrees. Interpretation of data relies upon the accuracy of the information. 
A particular problem arises in pedigree analysis when a blood sample obtained from a 
male who believes himself to be the father of a child is shown not to come from the true 
father. This is known as non-paternity and is a not uncommon occurrence. Non­
paternity may completely destroy the validity of RFLP analysis.
DNA investigations with a clinical application were first described in prenatal diagnosis 
of haemoglobinopathies [Kan and Dozy, 1978]. However, methods for identifying 
carriers in the various haemoglobinopathies have been well established prior to the 
development of recombinant DNA techniques since earners for these disorders are 
usually phenotypically abnormal. This was not the case for carriers of haemophilia A 
and an early application of the new molecular techniques was the use of DNA probes and 
restriction fragment length polymorphisms (RFLPs) to identify carriers of haemophilia A 
and to allow early pre-natal diagnosis of disease. In 1984, Harper et al described a DNA 
probe, DX13, linked to haemophilia A which was clinically useful and a second linked 
probe, S tl4, was soon described [Oberle et al, 1985A]. Within a short period of time, 
two intragenic probes were also described [Gitschier et al, 1985A; Antonarakis et al, 
1985A]. It was these four probes which were used in the present study.
The first RFLP to be described in the factor IX gene was the Taq I polymorphism. A 
preliminary description of this polymorphism relied upon a cDNA probe [Camerino et al, 
1984]. This was rapidly followed by a description of the same polymorphism identified 
with a genomic probe, known as probe VIII, which identified a constant band of 5.3kb 
and a polymorphic site giving a band of either 1.8kb or 1.3kb [Giannelli et al, 1984]. 
This is the first probe and enzyme combination used in this study.
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Two further intragenic RFLPs were quickly described [Winship et al, 1984], The first 
was the same F9 probe (VIII) but the enzyme is Xmn I. A polymorphic site close to 
exon c, within intron 3, showed an 11.5kb band in the majority of cases but in some 
instances this band was absent being replaced by two bands at 6.5 and 5.0kb. The Xmn 
I polymorphism is the consequence of a single C and G base transversion resulting in the 
formation of a Xmn I site in this region of the gene. In contrast to this, the Dde I 
polymorphism described (which is also apparent with the enzyme Hinf I) represents an 
insertion of 50 bp forming the rarer allele. This in turn probably represents a duplication 
of the flanking simple repeat sequence of the form [(CA/TA)mGT]n where m and n are 
independent integers. The original method used the probe XII although in this study 
now reported we used probe XIII.
The sequencing of the cDNA for the vWF gene has enabled partial length cDNA probes 
from the entire length of the vWF gene to be developed. The RFLP used in this study is 
a Bgl II polymorphism described by Veiweij et al [1985B] using an 1 lOObp vWF probe.
1.3 INHERITED DISORDERS OF COAGULATION
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H istorical Aspects
That a bleeding disorder exists which has X-linked inheritance has been recognised for 
over 150 years [Hay, 1813] and the term haemophilia was introduced in the nineteenth 
century. There are earlier references to a bleeding disorder affecting males from the 
second century AD when the Babylonian Talmud describes the decision of Rabbi Judah 
that the son of a woman whose three previous sons had bled to death following 
circumcision be excused from this rite [Wintrobe, 1985]. Addis in 1911 described how 
the abnormality in haemophiliac plasma could be corrected by adding normal plasma. 
He attributed this to a deficiency in prothrombin and when this was shown not to be the 
case his work was largely forgotten. The so-called "classic" theory of coagulation at that 
time proposed by Morawitz in 1904 only envisaged four coagulation factors: 
thromboplastin derived from damaged tissue or blood cells converting prothrombin to 
thrombin in the presence of calcium; thrombin then reacting with fibrinogen to form 
insoluble fibrin. The development of the one stage prothrombin time test by Quick in 
1935 allowed the preliminary classification of inherited disorders of coagulation. In 
haemophilia the prothrombin time is normal. At about the same time it was shown that a 
fraction of normal plasma collected the coagulation defect in haemophilia [Patek and 
Taylor, 1937]. This factor was referred to as anti-haemophiliac factor (AHF) or anti­
haemophiliac globulin (AHG). The thromboplastin generation test described by Biggs 
and Douglas in 1953 showed that there was plasma thromboplastin in an intrinsic plasma 
system. Applying this test to haemophiliac plasma detected an abnormality which was 
presumed to be due to the lack of AHF. A group of patients were identified who 
apparently had haemophilia but whose plasma would correct the defect of other 
haemophiliacs. The thromboplastin generation test showed that this subgroup had a 
defect of a serum factor. This defect was called Christmas disease after the name of the 
first patient described [Biggs et al, 1952]. At the same time Aggeler et al [1952] 
describing the same defect called the missing factor plasma thromboplastin component 
(PTC).
An International Committee devised standard nomenclature for coagulation factors in 
1962 based on Roman numerals [Wright, 1962]. AHF became factor VIII and 
Christmas factor or PTC became factor IX. Haemophilia was divided into Haemophilia 
A or classic haemophilia due to a defect in factor VIII and Haemophilia B or Christmas 
disease due to a defect of factor IX.
Von Willebrand disease was first described in 1926 in inhabitants of the Aland islands 
[von Willebrand, 1926]. Other reports followed and autosomal inheritance was
recognised. The disease was initially referred to as autosomal pseudohaemophilia. 
Unlike haemophilia, von Willebrands disease is associated with a prolonged bleeding 
time. For this reason, it was postulated that it was due to a defect in platelets but it is 
now known to be due to a variety of defects in the von Willebrand factor which is 
present in plasma.
Other inherited coagulation disorders such as factor VII deficiency are of historical 
importance since the recognition of these clinically and genetically distinct disorders 
sheds further light on the physiology of the coagulation cascade. However, these 




Haemophilia A is due to an inherited functional deficiency of coagulation factor VIII. 
This deficiency affects secondary haemostasis so that bleeding is likely to be a particular 
problem when larger blood vessels are involved or after initial vasoconstriction resolves 
[Bloom, 1987]. Although neonates may present with a cephalhaematoma, with 
excessive bruising at injection sites or with post-operative haemorrhage, more commonly 
the diagnosis is not suggested until late infancy. At this stage multiple areas of excessive 
bruising may raise the suspicion of non-accidental injury. In older children and adults 
haemarthroses predominate. Any joint may be involved although the large weight 
bearing joints cause most problems. Repeated haemarthroses often lead to secondary 
arthropathy which itself predisposes that joint to further episodes of haemorrhage [Rizza 
and Matthews, 1984].
Deep intramuscular locations are the other common sites of haemorrhage and may be 
spontaneous or follow relatively minor trauma. These haematomas may cause local 
pressure effects, for example the femoral nerve may be compressed by an iliopsoas 
haematoma. Inadequate treatment of these deep haematomas may result in cystic 
collections which are prone to secondary infection unless surgically removed 
[Valderrama and Matthews, 1965].
Although the incidence of intracranial bleeding appears to have fallen it is still the 
commonest cause of death following bleeding in haemophiliacs [Biggs, 1977]. The 
bleeding may be extradural, intradural or intracerebral and may follow relatively trivial 
head injury. In a recent series 47% of survivors had neurological sequelae [Eyster et al, 
1978].
Less common sites of haemorrhage are the renal tract, the upper airway and the 
gastrointestinal tract and for these sites local alternative pathologies need to be excluded.
I.4ii Treatment
Addis in 1911 showed that blood or normal plasma could correct the abnormality in 
haemophilia and treatment became a reality with the development of a technique to 
cryopreserve concentrated plasma factors [Pool et al, 1964]. Cryoprecipitate avoids the 
earlier problems of volume overloads and allows the preparation of highly concentrated 
lyophilised factor VIII which is stable for several months.
23
Mild haemophiliacs require intravenous treatment only if they have a haemarthrosis or if 
they are to undergo an operation or dental extraction. Those with more severe 
haemophilia may be candidates for home therapy as they are aware of the onset of 
haemorrhage before there is clinical evidence [Jones, 1977] and thus treatment can be 
initiated promptly. In some cases regular prophylaxis of spontaneous haemorrhages is 
appropriate.
Prior to the availability of factor VIII treatment, the average lifespan of a severe 
haemophiliac was estimated to between 20 and 30 years. Over that time a haemophiliac 
would suffer increasing disability and pain. Figures produced in the early 1980’s when 
factor VIII was widely available estimated that individuals suffering from haemophilia A 
had, on average, a 50 year lifespan. That is that the disease shortened their life by 20 
years [Weatherall, 1985]. The current problems with the HIV virus and AIDS may 
change this situation in the 1990's.
Unfortunately therapy is not without its drawbacks. First there is the need for 
intravenous injections and second there is the risk of transmission of infectious agents 
from pooled plasma preparations. Currently over 50% of regularly treated 
haemophiliacs have abnormal liver function tests and in the majority of cases this is 
believed to reflect viral hepatitis [Stevens et al, 1983]. The current method of 
preparation of factor VIII concentrate inactivates Epstein-Barr virus and cytomegalovirus 
and it is also now routine to screen donors for hepatitis B. However, almost all develop 
evidence of non-A non-B hepatitis (now known as hepatitis C) after treatment [Fletcher 
et al, 1983]. A recent study described evidence of progressive liver disease in 21% of 
haemophiliacs who had liver biopsy for persistently elevated liver function tests [Hay et 
al, 1985].
Currently the major concern relates to the transmission of human immunodeficiency 
virus (HIV) and the subsequent development of acquired immunodeficiency syndrome 
(AIDS). A recent survey found 1,201 UK haemophiliacs to be HIV positive with 85 
cases of AIDS and 47 deaths [Darby et al, 1989]. Seroconversion has been reported 
despite heat-treatment of factor VIII [White et al, 1986] and in the UK all blood donors 
are now screened for this virus. However, this does not apply to foreign sources of 




Any description of current investigations of coagulation disorders contains a confusing 
collection of abbreviated terms referring to different types of assays. The nomenclature 
is somewhat haphazard, reflecting the understanding of the time of development of an 
assay rather than a rational description of events. These terms are even now in a state of 
flux and so anyone reading the literature of present day investigations has to be 
conversant with various terms for the same investigations.
The defect in factor VIII can be measured functionally in plasma using a coagulation test. 
Factor VIII assayed in this way is referred to as VIII:c. Alternatively factor VIII may be 
measured antigenically using the autoantibodies which develop in some severe 
haemophiliacs after multiple treatment. This is referred to as factor VIII:Ag. An 
individual haemophiliac with a given level of VIH:c is likely to have a slightly lower level 
of VIIIiAg, but in most individuals the levels are proportionate. However in a few 
individuals the measured antigen is much higher than the functional assay. These 
individuals are said to have cross reacting material: they are described as CRM+. Those 
individuals with antigen levels equivalent to functional VIIIc are CRM- [Peake and 
Bloom, 1978], The CRM status will be the same for all affected individuals in a 
kindred. Confusion arises because early immunological studies, using antibodies raised 
in animals detected an antigen which was referred to as factor VIII related antigen or 
factor VIIIR:Ag. It is now realised that this is an antigenic function of the much larger 
molecule von Willebrand's factor which is bonded non-covalently with factor VIII:c in 
plasma but does not play a role in haemophilia A.
The clinical severity of haemophilia shows a correlation with the degree of reduction in 
the functional level of factor VIII with mild cases having VIII:C over lOiu/dl, moderate 
2 - 1 0 iu/dl and severe under 2 iu/dl.
Langdell et al in 1953 described the one stage modified activated partial thromboplastin 
time using factor VIII deficient plasma to assay factor VIII coagulant activity. This test 
is still used in laboratories today.
I.4iv Genetic Aspects
Haemophilia has been known to run in families since antiquity. In the Jewish Talmud 
from the 5th century BC boys in these families were excused circumcision [Wintrobe,
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1985]. Early descriptions showed the characteristic features of X-linked recessive 
inheritance [Macklin, 1928]. In 1952 haemophilia B was distinguished from 
haemophilia A and both were accepted as X-linked recessive traits. In families with red- 
green colourblindness the locus for haemophilia A but not for haemophilia B showed 
linkage [Haldane and Smith, 1947].
Hence males with only a single copy of the X chromosome are hemizygous for X-linked 
genes and are either affected or unaffected with haemophilia. The female with two X 
chromosomes can carry the mutant factor VIII and will usually be clinically normal. In 
every female at around the 2000 cell stage one X chromosome is largely inactivated (X- 
inactivation, Lyonisation), [Lyon, 1962]. This pattern of inactivation remains constant 
for all descendants of each cell. In some carrier females by chance mainly the normal 
factor VIII gene will be inactivated and these females may show mild haemophilia. 
Conversely some carrier females will mainly inactivate the abnormal factor VIII gene and 
have normal laboratory investigations whilst the majority will occupy an intermediate 
position.
There are two areas of difficulty in genetic counselling of affected families: the 
determination of female earner status and selective prenatal diagnosis. A female has to 
be a carrier (ie is an obligate carrier) if she is the daughter of a haemophiliac, has two 
haemophiliac sons or has a haemophiliac offspring and other affected maternally related 
relatives.
Since haemophilia has been recognised to be a genetic disorder, there has been interest in 
detection of possible carriers. Identification of heterozygotes for haemophilia A by 
laboratory means was first attempted by Merskey and Macfarlane in 1951 but the results 
were not sufficiently discriminating to be useful. Bennett and Huehns [1970] described 
the production of a rabbit antibody to crude human factor VIII and used this to measure 
what they believed to be immunologically competent but biologically inactive factor VIII. 
They noted that carriers of haemophilia A appeared to have lower levels of factor VIII 
activity measured by a functional assay compared to the protein acting against factor VIII 
antibody. It became apparent from work published by Zimmerman et al in 1971 that this 
antibody acted against a protein which was missing in patients who had severe von 
Willebrand's disease. This protein came to be known as factor VIII related antigen 
(FVIIIR:Ag). Results published in the early 1970’s by various groups [Bennett and 
Ratnoff, 1973; Rizza et al, 1975; Prentice et al, 1975; Meyer et al, 1975] confirmed the 
finding that carriers tended to have a low FVIIIC and a normal FVIIIR: Ag and that it was 
possible in many cases to identify earners. However, none of these groups could 
identify 100% of carriers by this technique. Bennett and Ratnoff [1973] looked at 18
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daughters of known carriers and identified 9 of these as earners but at the time of 
publication none of the 18 women had had any sons and so confirmation of the 
technique was uncertain. Rizza et al [1975] conducted a blind study whereby those 
performing the assay did not know the carrier status of the individual tested. Looking at 
34 normal individuals and 34 known carriers they found that 71% of carriers could be 
identified on the basis of the ratio of factor VIII activity to factor VIII related antigen. 
Prentice et al [1975] used discriminant analysis to calculate betting odds of carrier status. 
Investigating 32 possible carriers of haemophilia A they could only give relative betting 
odds greater than 5:1 of carrier status or non-carrier status in 69% of women tested. One 
woman investigated and shown to have odds of 1 0 .6 : 1  of not being a earner 
subsequently gave birth to a severely affected haemophiliac son. Meyer et al [1975] 
measured factor VIII activity and factor VIE related antigen in 49 carriers and 31 normal 
women. The data was analysed by four statistical approaches. Discriminant analysis 
appeared to be the most useful statistical method but even with this method 16% of 
normals and 18% of earners were misclassified, overlapping with the other group. The 
World Health Organisation published a memorandum on the subject of carrier detection 
of haemophilia A and B with recommendations for the standardisation of laboratory 
techniques and statistical methods [Akmeteli et al, 1977]. It was clear that the 
combination of accurately performed coagulation assays and analysis of pedigree data 
could alter the calculation of a prediction of likelihood that any particular woman at risk 
was in fact a earner. Nonetheless, the uncertainties for many women remained since 
many could only be offered "betting odds" of carrier status rather than absolute answers. 
Published studies attempted to determine the specificity and sensitivity of laboratory 
techniques and to determine the cause of interlaboratory variation but this failed to 
eradicate the probabilistic value of the calculated results and the associated limitations 
when applied to carrier detection [Klein et al, 1977; Kirkwood et al, 1977].
Details other than pedigree information and coagulation results may help to distinguish 
carrier females. As early as 1960, Rapaport, Patch and Moore had shown that the 
"between day" variation in VIII:C assays was greater than the variation between 
duplicates on the same day suggesting that averaging of replicates obtained over time 
would provide a more representative VIII:C level for a woman than a single 
determination or the average of replicates obtained on a single day. In some parts of the 
world, the known linkage between haemophilia A and G6 PD deficiency can be helpful in 
a family where both diseases are present [Filippi et al, 1984]. However in the UK, 
G 6 PD deficiency is rare. Improved discrimination between carriers and non-carriers 
was reported in a study where DDAVP was infused into women prior to sampling 
[Kobrinsky et al, 1984]. Post DDAVP haemophilia carrier detection was increased from 
85% with 10% false positive and 20% false negative assignments to 95% with 5% false
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positive and 5% false negative assignments. An immunoradioactive assay of the VIII:C 
antigen (VIIICAg, now called VIIIAg) was shown to give comparable results in carrier 
detection to the functional assay of VIIIC but the results were more reproducable 
between samples where plasma had been frozen [Peake et al, 1981]. It has been 
suggested that the improved stability of this technique would allow samples to be more 
easily transported to a central laboratory to allow assays where results are difficult to 
interpret such as during pregnancy [Hoyer et al, 1982]. A recent study has highlighted 
the importance of the effect of age on both FVIII:C and VWF:Ag. Values of both these 
factors are higher in the very young and very old and reach their lowest level at age 25 to 
30 years. This study also reported significantly higher levels of both factors in women 
whose blood group was not group O [Graham et al, 1986].
Many women who are obligate carriers or are advised after testing that they are likely to 
be carriers of haemophilia often choose not to have a family or to limit their family in 
some way. The earliest method of prenatal diagnosis was fetal sexing following 
amniocentesis. Any male child terminated following this procedure had only a 50% 
chance of being affected which made this diagnostic method unacceptable to many 
female earners. In 1979, both Firshein et al and Mibashan et al described prenatal 
diagnosis of coagulation disorders following fetal blood sampling and coagulation factor 
assays. If amniocentesis showed a male fetus, the fetoscopy was performed at about 19 
weeks gestation with fetal blood sampling. Factor assay allowed accurate diagnosis 
prior to termination. Termination of pregnancy inevitably meant a late termination of 
pregnancy. The development of chorionic villus sampling in the first trimester of 
pregnancy allowed DNA analysis and early prenatal diagnosis. If haemophilia is 
diagnosed in the fetus, termination of pregnancy is offered at a much earlier stage of 
gestation. Initial reports have shown this to be a more acceptable method of prenatal 
diagnosis than those which preceded it.
Thus at the time that this study was undertaken women seeking advice about earner 
status could only be offered coagulation testing which does not detect all earners 




I.5i and I.5ii Clinical Aspects and Treatment
Clinically haemophilias B and A are indistinguishable and the clinical features and natural 
history are as outlined in section I.4i.
Treatment with cryoprecipitate is ineffective and most patients are treated with highly 
purified factor IX concentrate. As in all coagulation disorders antifibrinolytic agents may 
have some place in controlling bleeding especially after dental extraction. DDAVP does 
not increase the level of factor IX and so has no role in the treatment of haemophilia B.
The problems associated with therapy are the same as those encountered in haemophilia 
A: in particular the development of antibodies to factor IX, liver disease and viral 
transmission.
I.Siii Laboratory Aspects
Factor IX may also be assayed functionally, factor IX:c, or antigenically, factor IX:Ag. 
Combining information from functional and immunological assays, haemophilia B 
families can be divided into B+ where there is a low IX:c level but a normal IX:Ag, B- 
where a low IX:c is accompanied by a similarly low IX:Ag and Br where a low IX:c is 
associated with a reduction of IX:Ag to a lesser degree [Parekh et al, 1978].
Factor IX is a vitamin K dependant coagulant factor synthesised in the liver. It has close 
homology with factors II, VII and X as well as protein C which are also vitamin K 
dependant [Kurachi and Chen, 1987].
Patients with haemophilia B have a prolonged partial thromboplastin time and factor IX 
can be assayed using a coagulation assay and factor IX deficient plasma. Unlike 
haemophilia A the type of assay used may affect the resulting level found [Bloom, 
1981]. This may be because some assay methods underestimate factor IX. Haemostasis 
requires a lower proportion of factor IX than factor VIII.
It has been apparent for some time that there are many valiants of haemophilia B as a 
result of different structural abnormalities of the factor IX protein [McGraw et al, 1985A 
and 1985B]. These variants began to be recognised when factor IX was assayed by 
immunological methods as well as by coagulant techniques.
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I.5iv Genetic Aspects
Haemophilia B is inherited as an X-linked recessive trait in exactly the same manner as 
haemophilia A.
Carrier detection in haemophilia B does not have the advantage of the known 
discrepancy in ratio between VIII:c and vWF (previously referred to as VIIIR:Ag). 
Measurement of IX:c only in obligate carriers identifies carrier status in less than 50% 
[Simpson and Biggs, 1962]. Plasma factor IX antigen is present in excess of the 
amount of factor IX antibody in haemophilia B+ (or CRM+) families but in haemophilia 
B- (or CRM-), which is the more common form of haemophilia B, factor IX antigen and 
factor IX activity are present in equivalent amounts. Orstavik et al [1979] measured 
factor IX antigen and factor IX activity in 40 controls, 18 B- carriers and 10 B+ carriers 
and constructed statistical tolerance regions graphically for earners and for controls. 
Only 17 out of the 40 controls were outside the 90% tolerance region for carriers. In the 
B- group 10 of the 18 carriers were outside the 90% tolerance region for earners 
whereas in the B+ group only 1 individual fell within the 90% tolerance region for 
controls. Although measuring factor IX antigen as well as activity improved earner 
detection, particularly for B- families, there were still many women not detected as 
carriers by this method and there was considerable overlap with the control group.
Second trimester prenatal diagnosis is possible for haemophilia B although, like other 
vitamin K dependant factors, factor IX remains at a relatively low level until the third 
trimester. This makes the cut off point between disease levels and normal less distinct 
than in the case of haemophilia A. Also factor IX antigen is present in amniotic fluid so 
that any sample contamination may affect the result. This is not the case in haemophilia 
A [Thomson, 1984]. As is the case for haemophilia A earner detection by coagulation 
assay is unable to give definitive answers. Pre-natal diagnosis must be done late, is 
technically difficult and has the added risk of sample contamination.
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1.6 VON WILLEBRAND DISEASE 
I.6i Clinical Aspects
Von Willebrand disease is a heterogeneous group of conditions which in common 
involve abnormalities of the von Willebrand factor. These disorders affect primary 
haemostasis so that affected individuals suffer from bruising and mucosal bleeding. 
Children may present with bleeding from the gastrointestinal or genitourinary tracts and 
in older women menorrhagia is a common complaint. After surgery or dental extraction 
bleeding is excessive and occurs immediately after injury [Rizza and Matthews, 1984]. 
The severity varies both within and between affected families and the most severely 
affected may have deep intramuscular bleeding and haemarthroses in addition to the 
mucosal bleeding and rival the haemophilias in severity.
The clinical situation in vWD varies from that in haemophilia. The autosomal dominant 
form is relatively common. However it is usually mild and it is extremely unlikely that 
an individual would ever seek pre-natal diagnosis for this condition with a view to 
termination of pregnancy although it is possible that knowledge of the presence of von 
Willebrand disease would be useful for planning delivery. Since it is an autosomal 
dominant condition, affected individuals can be identified by conventional clotting tests 
and so the issue of carrier detection rarely arises. Occasionally, even after testing on 
several occasions, clotting studies may produce equivocal results in which case DNA 
studies may help to elucidate the problem. Similarly, a second disorder interfering with 
blood clotting, such as thrombocytopenia or drug induced problems may make 
coagulation studies difficult to interpret and in this situation DNA studies may be helpful. 
The situation in the rare type III vWD is different. This is a homozygous or double 
heterozygote disorder which causes a severe bleeding disease. Parents of an affected 
individual might well seek genetic counselling and pursue the possibility of pre-natal 
diagnosis. Not surprisingly, published series of studies of vWD in families investigated 
by RFLP or other DNA based investigations have tended to concentrate on this rare but 
serious form of vWD.
When looking at the present study it is interesting to note the relatively small number of 
affected families registered at the Regional Haemophilia Centre. This does not bear a 
close relationship to the estimated prevalence of vWD but does reflect the experience of 
other regions. Many individuals with von W illebrand disease are relatively 
asymptomatic and are therefore less likely to attend clinics for regular follow up. The 
greater difficulty in obtaining DNA from relatives of probands may also reflect the lower
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motivation of a family affected by a disorder which is perceived to be less serious than 
haemophilia.
I.6ii Treatment
DDAVP stimulates the release of von Willebrand factor from endothelial cells and is the 
treatment of choice in type I and some type II von Willebrands disease. It is contra­
indicated in type lib vWD where the released abnormal vWF causes aggregation of 
unstimulated platelets. Until recently cryoprecipitate was recommended for these 
patients who did not respond to DDAVP as it is rich in vWF [Bennett and Dormandy, 
1966], however, with the increasing anxiety about the risk of transmission of the HIV 
virus, there is now a move to usage of moderately pure FVIII concentrates which may 
contain lower levels of vWF but which are heat treated and therefore thought to be safer 
than cryoprecipitate [Berntorp and Nilsson, 1989]. Treatment with cryoprecipitate 
restores the bleeding time for up to 12 hours. The level of factor VIII is restored for a 
much longer period and so cannot be used as a guide to therapy [Holmberg and Nilsson, 
1985].
Inhibitors of fibrinolysis may be used in the treatment of von Willebrand disease and are 
of particular value after dental extraction. Since DDAVP also stimulates release of 
plasminogen activator a fibrinolytic inhibitor such as tranexamic acid is usually 
administered at the same time [Ludlam et al, 1980].
I6.iii Laboratory Aspects
The vWF protein has two functions. It cross-links platelet membrane to the collagen 
exposed in damaged endothelium under conditions of high shear rates. However, it also 
acts as a protective earner for factor VIII in the circulation. The tests used to identify 
vWD reflect these two different functions. FVIII is low in vWD not because of 
abnormalities in the FVIII protein but because is decays more rapidly in the absence of 
its earner protein. A prolonged bleeding time reflects the abnormal platelet binding to 
collagen. vWF:Ag is also measured directly. Finally platelet aggregation in the presence 
of the antibiotic ristocetin is measured (Ricof). Ristocetin promotes spontaneous 
aggregation of platelets but this response is reduced in vWD. The exception to this is 
type IIB vWD where there is increased platelet aggregation even at low concentrations of 
ristocetin. The basic tests for vWD are completed by checking the platelet count and 
platelet aggregation to exclude a bleeding disorder secondary to a platelet abnormality. 
Many laboratories now extend the investigation of vWD to include electrophoresis of the 
protein. This will identify the vWF multimers and the subtype of vWD will be assayed
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according to the abnormality seen. Type I makes up 80% of patients with vWD and is 
subdivided further in A, B or C. Type II makes up the majority of the remainder and is 
subdivided A to F according to the multimer analysis and laboratory results. Type III is 
the rare autosomal recessive severe form of the disease [Tuddenham, 1989].
I.6iv Genetic Aspects
M ost families show autosomal dominant inheritance for von W illebrand disease 
including the original description from the Aland islands [von Willebrand, 1926]. The 
recent isolation of the gene for von Willebrand factor and its localisation to chromosome 
12 is consistent with these observations. In addition several families have been 
described with apparent autosomal recessive inheritance of particularly severe disease 
[Holmberg and Nilsson, 1985].
Since, for the vast majority of families, it is a dominant disorder, the problem of carrier 
detection seen in the X-linked disorders does not arise. There may be difficulties in 
identifying affected individuals since the clotting studies will show both inter and intra 
individual variations and it may be necessary to repeat tests several times. Pre-natal 
diagnosis is unlikely to be requested in the common dominant inherited disorder as the 
bleeding problems are rarely severe. However the recessively inherited form of vWD 
may resemble severe haemophilia but with mucosal bleeding as an extra problem. 
Families with one affected child may then seek PND for a future pregnancy. At the time 
that this study was undertaken, this could only be achieved by fetal blood sampling and 
second trimester diagnosis.
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CHAPTERIT - ATM OF THE PRESENT INVESTIGATION
This project was initiated in 1985/86. As indicated at that time the coagulation tests 
available for carrier detection of haemophilia were inadequate. Pre-natal diagnosis of 
any coagulation disorder could only be achieved using second uimester blood sampling. 
The overall aim of this project was to utilise the newly available DNA RFLPs in families 
with common inherited coagulation disorders to see if they improved detection of gene 
carriers and could be used for first trimester pre-natal diagnosis.
Specific aims were as follows:-
1. To obtain DNA samples from a large number of haemophilia A families and analyse 
them with intragenic factor VIII and linked extragenic probes and to compare the results 
with the two sets of probes and coagulation test results.
2. To obtain DNA samples from a large number of haemophilia B families and analyse 
them with intragenic factor IX probes and to compare the results with the probes with 
historical coagulation data.
3. To obtain DNA samples from a large number of von Willebrand disease families and 
to analyse them with an intragenic probe and to compare the results with coagulation test 
results.
ITT - PATIENTS. MATERIALS AND METHODS
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III.l PATIENTS
Records of patients were obtained from the Regional Haemophilia Reference Centre at 
the Royal Infirmary, Glasgow, and from the Duncan Guthrie Institute of Medical 
Genetics, Glasgow. Attempted total ascertainment in the West of Scotland revealed 
twelve families with haemophilia B with more than one person affected, ten of whom 
were willing to participate in the study. A further two families were referred for 
investigation from other centres. All families were of Caucasian origin. Ten families 
with haemophilia A were selected from the register who had more than one affected 
member, several possible carrier females and who lived reasonably locally. One family 
was of Malaysian origin, the others were all Caucasian. A further six families presented 
themselves during the course of the study requesting investigation. Eleven families were 
ascertained who had more than one individual affected with von Willebrand disease. 
Ten families were of Caucasian origin. There was one family with severe recessive 
vWD who were Asian and the marriage was consanguinous. An extended pedigree was 
obtained from all families and blood samples obtained for DNA analysis.
DNA from unaffected individuals, used to calculate allele frequencies in the normal local 
population, was obtained from DNA already stored in the Duncan Guthrie Institute of 
Genetics or from spouses of family members in the present study.
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III.2 MATERIALS
DNA PROBES - Probes factor 9 (VIII) and factor 9 (XIII) were kindly donated by 
Professor G.G. Brownlee. Probe factor 9 (VIII) is a 2.5kb segment of the factor IX 
gene containing 2.5kb of introns and the "d" exon. It identifies two bands in Taq I 
digested DNA from males and two or three bands in Taq I digested DNA from female 
subjects. The 5.3kb band occurs in all subjects and the polymorphic fragments were 
1.8kb or 1.3kb. When DNA is digested with Xmn I and probed with factor 9 (VIII) 
only a single band is apparent in males, 11.5kb or 6.5kb, whereas females may be 
homozygous for either fragment or heterozygous, 11.5kb/6.5kb. Probe factor 9 (XIII) 
similarly only identifies a single band in Dde I digested male DNA, 1.75kb or 1.7kb, 
whereas females may be homozygous for either fragment or heterozygous.
Four probes were used to investigate haemophilia A, Stl4, DX13, F8 A and F 8 B. S tl4  
is a fragment of 9kb which reveals a polymorphic system with at least ten allelic 
fragments in addition to fragments of constant size in Taq I digested DNA (it also 
recognises a polymorphism on Msp I digested DNA). It lies in the q26-qter region of 
the X chromosome although not within the factor VIII gene. In this study alleles were 
numbered 1 - 1 0  according to size rather than using the actual kilobase measurement of 
each allele [method used in Youssoufian et al 1986]. S tl4  was supplied by Dr. J-L. 
Mandel. The international marker symbol for it is DXS52. DX13 (international marker 
symbol DXS15), supplied by Dr. K. Davies, is a cloned sequence of DNA localised to 
band Xq 28 of the X chromosome which recognises a polymorphism in Bgl II digested 
DNA. As well as four invariant bands males have either a 2.8kb band or a 5.8kb band, 
women may be heterozygous 5.8kb/2.8kb or homozygous for either band. DX13 does 
not lie within the factor VIII gene. F8 A (exon 17-18) supplied by Dr. Lawn, is a 647bp 
intragenic factor VIII probe which recognises a polymorphism in Bel I digested DNA. 
Males have either a 1.2kb band or a 0.9kb band, women may be heterozygous or 
homozygous. F8 B (exon 26) is supplied by Dr J. Toole. It is a 1.8kb fragment of exon 
26 of the factor VIII gene which recognises a polymorphism in Bgl I digested DNA. 
Males have either a 5kb fragment or a 20kb fragment, women may be heterozygous or 
homozygous.
The probe used to study von Willebrand disease was donated by Dr CL Verweij. It is a 
lOObp cDNA fragment of the von Willebrand factor gene,named pvW Fl 100,which 
recognises a two allele polymorphism in Bgl II digested DNA with a band at either 9kb 
or 7.4kb as well as two invariant bands at 13kb and 4.9kb. Since the gene is localised to 
an autosome, chromosome 1 2 , both males and females can be heterozygous or 




DNA was extracted from whole blood in EDTA using the method of Kunkel et al 
[1977]. Eight micrograms of DNA were digested overnight using thirty to fifty units of 
restriction enzyme. The resulting fragments were electrophoresed in 0.8% agarose gels 
and then stained with ethidium bromide. The only exception was samples being 
investigated for Haemophilia B with the Dde I polymorphism and the probe XIII where a 
long gel of 1.2% agarose was used. Each lane was examined and photographed in 
ultraviolet light to check for complete digestion before transfer to nitrocellulose or 
Hybond N nylon based transfer membrane (Amersham) by Southern blotting [Southern, 
1975]. DNA was fixed to the transfer membrane by a five minute UV crosslinking 
treatment.
DNA probes were labelled with either nick-ttanslation (using the Amersham kit) or 
hexanucleotide labelling [Feinberg and Vogelstein, 1983]. The filters were hybridised 
with denatured probe at 42°C in 50% formamide, lx  Denhardts solution, 5x SSC, 
20mmol NaH2 PC>4 (pH 6 .8 ), O.lmg/ml heat denatured salmon sperm DNA, 20g/ml poly 
A and 10% dextran sulphate. Hybridisation was allowed to take place over 48 hours. 
Excess probe was then washed off in 2x SSC, 0.1% SDS at room temperature for 30 
minutes followed by washes at 63°C in 0.5x SSC, 0.1% SDS or O.lx SSC, 0.1% SDS 
for 30 minutes, depending upon the final stringency required. Filters were then exposed 
to X-ray film using intensifying screens at -70°C for various periods of time.
The size of bands produced in each lane of DNA could be identified by running 
concurrently a lane containing fragments of DNA of known size: a DNA ladder. The 
data obtained for each RFLP for the individuals tested is contained in the appendix. 
Interpretation of the data required a knowledge of the family pedigree. RFLPs in this 
context are used simply as markers of the relevant gene (or area close to the gene in the 
context of extragenic probes) and allow the inheritance of a particular gene to be traced. 
Thus a mother with alleles A/B may have a son with either. If the son with allele A has 
haemophilia, then any daughter inheriting a maternal allele A is a carrier and any 
daughter with allele B is not a carrier.
III.3ii Haematological Investigations
These methods are all described in detail in a standard haematology laboratory textbook 
[Dacie and Lewis, 1984].
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Bleeding time is measured by the standardised template method using a commercially 
manufactured blade ( Simplate, General Diagnostic). VIIIc in this study is measured 
functionally using a one stage assay. The immunoelectrophoretic method of Laurell 
[1966] is used to measure von Willebrand factor antigen (VWF:Ag) and ristocetin co­
factor (VWF:RCo) is measured using a platelet aggregometer and applying the method 
described by McFarlane [1975].
I l l  - 3iii Interpretation and Relaying of Results
Results of DNA studies were interpreted by myself but checked by Dr. Connor. The 
individuals concerned were informed of the results. Where possible, women were seen 
by myself, informed of the results and the limitations of the tests explained. 
Subsequently, they received a letter stating the information presented at interview. 
Women who were unable to attend a clinic were informed of the results by letter. All 
women were offered the opportunity of further counselling as required.
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CHAPTERTV - RESULTS 
IV .l HAEMOPHILIA A 
IV .li Individuals Tested
In the West of Scotland, 215 males with haemophilia A are registered with the Regional 
Haemophilia Centre. This represents an estimated prevalence 1/6500 males. In view of 
the large numbers involved, it was decided to select local multiplex families who were 
interested in having the studies performed upon themselves. During the study, 
individuals presented themselves requesting genetic counselling and these families were 
also included. In all, sixteen families were studied. The pedigrees of these families are 
shown in figure 4. Altogether, a total of 216 individuals were tested of whom 40 were 
affected males, 38 were obligate carrier females and 71 were females at risk. The DNA 
results and haematological results for tested members of each family are presented in 
appendix 1 .
IV .lii Allele Frequency
The RFLPs used in this study are illustrated in Fig 5. The allele frequency for each 
RFLP in unrelated X chromosomes in individuals not affected by haemophilia A was 
measured. In view of the multiple allele system of the St 14 RFLPs and the relatively 
small numbers in this study, no attempt was made to record allele or heterozygote 
frequency within the general population although the results obtained from the study will 
be presented in a later section. The results for the three other RFLPs are contained in 
table 1 .
The allele associated with haemophilia A in the same 3 RFLPs is shown in table 2. 
IV .liii Female Relatives Investigated
Details of all obligate and potential carriers who were investigated in this study are 
shown in table 3.
Thirty eight obligate carriers were tested although only thirty were tested with all four 
probes. The information obtained was useful not only as part of pedigree studies but 
also to show how many obligate carriers in the population studied are informative, ie 
heterozygous for any one probe and so could be offered prenatal diagnosis should they 
seek it. See table 4.
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50% of obligate earners were informative with F 8 A probe whilst only 17% were 
informative with F 8 B. There were two women not informative for F8 A who were 
heterozygous with F 8 B so that in all 55% of obligate carriers were informative with an 
intragenic probe. 47% of carriers were informative using DX13. Only 35 obligate 
earners were tested with St 14 and 29 (83%) of these were informative. These 35 
obligate carriers were tested with both extragenic probes and in all 32 (91%) of them 
were informative. Twenty seven (90%) of the thirty women tested with all four probes 
were informative.
Seventy one females who had at least a Vs chance of being a carrier from pedigree were 
tested with DNA probes. Twenty nine (41%) had definitive determination of carrier 
status on the basis of the two intragenic RFLPs. 19 of these relied upon information 
from F 8 A, 8  from F8 B and two from both. A further 22 (31%) had refined genetic 
information on the basis of extragenic probe information. One of these relied upon 
information from DX13, two from Stl4 and 19 from both. In 20 females at risk (28%) 
DNA analysis was unhelpful. In 9 of these the problem was maternal homozygosity for 
all four probes tested and in the remaining 11, absence of DNA samples from one or 
both parents or in one case grandparents, prevented interpretation of the data from the 
female at risk (Table 5). Use of the S tl4  probe with MspI digestion of DNA rather than 
Taq I which was used throughout the study failed to reveal any polymorphic sites 
amongst the 9 mothers homozygous for all four probes.
19 females were identified as carriers (27%) and 32 were identified as non earners 
(45%).
IV .liv  Non Paternity
In two families, the results of DNA studies suggested that siblings had different fathers 
although the family history had not suggested this. In pedigree 7402, the alleles for the 
four RFLP probes which are linked with haemophilia A are 1.2kb, 5kb, 2.8kb and 7kb 
(In the order F8 A, F8 B, DX13 and Stl4) See figure 6 . These have been inherited by 
individual 118 from her mother and, deriving information from 118 would give her father 
the genotype 1.2kb, 20kb, 2.8kb and 5kb. Neither 114 nor 116 have inherited the 20kb 
allele of F8 B and 114 does not have the Stl4 allele of 5kb.
In pedigree 7405, looking at the results of F8 A it is assumed that 112 and 114 are both 
0.9kb, 0.9kb. Since the 0.9kb fragment is linked with haemophilia A and has been 
inherited by III11 and III13 from their mother, it is clear that their father had a 1.2kb
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fragment and consequently could not have been the same person as the father of III8  
who is homozygous for the 0.9kb fragment. It is, however, still possible to advise 
individual III8  that she is not a earner for haemophilia A on the basis of the results 
obtained from the St 14 probe.
IV .lv  Recombinants
No recombination between the disease trait and the two intragenic factor VIII RFLPs 
was observed in 22 phase known informative meioses. Similarly, no recombinants were 
observed between the factor VIII gene and DX13 in 14 phase known informative 
meioses. However, for S tl4, three recombinants were observed amongst 28 phase 
known meioses. In pedigree 7402, (figure 7), there were two recombinants in a sibship 
of 13. Individual 118 is a earner for haemophilia A. With the St 14 RFLP, the 
haemophilia A is linked with allele 7. However, two haemophiliac sons have inherited 
the allele 5 suggesting recombination between the haemophilia gene and the St 14 allele 
site in the X chromosome. Similarly, in pedigree 2218, individuals 113,115 and 117 are 
all obligate carriers of haemophilia A. Individuals 113 and 115 have the Stl4 alleles 2 and 
7 and the haemophilia A is linked with the allele 7. Individual 117 has the alleles 2 and 3 
with haemophilia A now linked to allele 3. This would suggest a recombination in the 
maternal alleles between the gene for haemophilia A and the site of the St 14 alleles.
IV .lv i Coagulation Studies
21 obligate carriers had FVIIIc and vWFAg measured and these earners are listed in 
table 3 with coagulation results in appendix I. There were 24 possible carriers who had 
coagulation studies and who could also be assigned as carriers or non carriers as a result 
of DNA studies(table 6 ). Most of these women only had coagulation tests performed on 
one occasion. Where results were already available from the Haemophilia Centre, these 
were combined with the tests performed during this study and the results presented are a 
mean of these results. There was one obligate carrier 7319 113 and one potential carrier 
7405 III6  who were pregnant when these studies were made. The relative odds of each 
possible earner being a carrier were calculated using the graph contained in the paper 
publised by Prentice et al 1974. This was chosen as, at the present time, this is the data 
used locally to advise possible earners of their risk from information obtained from 
coagulation studies. Of the 11 assigned earner status as a result of DNA studies, six 
would have been given odds greater than even that they were carriers from coagulation 
studies. However, five would have been given odds greater than even that they were not 
carriers. Of these five, three were assigned as earners from information obtained using 
intragenic probes whereas two relied upon extragenic probes (table 6 ). All of the 13
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women assigned as non carriers would have been given odds against their being carriers 
from the results of coagulation studies.
These coagulation results are displayed diagramatically (Fig 8 ) and show clearly how 
gene probes improve the odds either for or against carrier status which will allow 
improved carrier detection.
IV .lv ii Linkage with G6PD Deficiency
Individuals III and 113 in Pedigree 7409 who are both haemophiliacs had undetectable 
levels of G 6 PD. Their sister 112 is identified as a earner of haemophilia from the 
information obtained from the S tl4  probe. Her level of G 6 PD is 3.3iu/gHb (normal 
range 8.5-16.9iu/gHb) and this would suggest that she is heterozygous for the abnormal 
G6 PD gene. Thus G6 PD deficiency, haemophilia A and S tl4  are linked in all three 
individuals (Fig 9).
In this study this is the only family where G6 PD deficiency was identified. This family 
originated from Malaysia although they were living in Glasgow at the time of the study.
IV .lv iii Linkage with Colour Blindness
There was a history of red/green colour blindness within pedigree 7407 (see Fig 10) 
which had been confirmed by the local ophthalmologist. Five out of nine males in the 
third generation were colour blind. Their maternal grandmother (12 in the pedigree) was 
an obligate earner for haemophilia A. She was non informative with intragenic probes 
but was informative with both DX13 and St 14. The daughters of this woman who were 
the mothers of the colour blind men (112 and II12 in the pedigree) were shown not to be 
earners by extragenic probes. They were both heterozygous for the DX13 RFLP, the 
2.8kb allele being the maternal allele from her non affected X chromosome and the 5.8kb 
allele being paternal. Similarly, they were both heterozygous for S tl4 , the allele 
numbered 8  coming from the maternal non-affected X chromosome and the allele 3 
coming from the father. One colour blind son (IEI3) and one non-affected son (III5) of 
1 1 2  were studied and showed that the alleles inherited from 1 2  were not associated with a 
diagnosis of colour blindness and the colour blindness must have originated in II (their 
maternal grandfather. The colour blind sons of 1112 (III17 and III18) and one non- 
affected (III 19) showed the same results. There was no genetic crossover noted between 
the gene for colour blindness and the extragenic probes S tl4  and DX13 in these five 
individuals.
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Lod scores calculated in this family between colour blindness and DX13 and S tl4  were 
maximum at a recombination fraction of 0 and gave a result of 0.96. Computer 
programme LINKAGE version 5.03 was used to calculate the lod score [Lathrop and 
Lalouel, 1984].
IV .lix  Prenatal Diagnosis
During the course of this study, early prenatal diagnosis was requested by one obligate 
carrier. The family pedigree is 7319. (See fig 4.) 113 is an obligate carrier as she has an 
affected brother and has had second trimester prenatal diagnosis and termination of 
pregnancy of an affected male foetus. As shown in fig 11, she is heterozygous for the 
intragenic F 8 A RFLP and her normal sons have the 0.9kb fragment. The foetus was 
tested at 9 weeks of pregnancy from DNA obtained by transcervical chorionic villus 
sampling. Since this time, the baby has been bom and is a female child. A total of 10|ig 
of DNA was obtained allowing the test to be done in duplicate. It has received the 1.2kb 
fragment and hence the mutant factor VIII gene. Fig 11 also shows results with a Y 
specific probe GMGY7 and absence of hybridisation to the DNA from the foetus shows 
that it is female. This was confirmed cytogenetically.
No OF No OF % OF
PROBE CHROM OSOM ES RFLP EACH EACH
TESTED (kb) ALLELE ALLELE
0.9 34 75.6
F 8 A 45 1.2 11 24.4
5 21 80.8
F 8 B 26 20 5 19.2
2.8 30 62.5
DX13 48 5.8 18 37.5
TA BLE 1 - R FLP FREQUENCIES IN NORM AL INDIVIDUALS IN 
TH R EE RFLPS USED IN INVESTIGATING 
HAEM OPHILIA A
No OF % OF
PROBE RFLP No EACH EACH
(kb) TESTED ALLELE A LLELE
0.9 8  50
F 8 A 1.2 16 8  50
5 11 85
F 8 B 20 13 2 15
2.8 12 75
DX13 5.8 16 4 25
TABLE 2 - PERCENTA G E OF EACH A LLELE LINKED W ITH  






FEM ALES AT R ISK
NOT CARRIERS NON-
I NF ORMAT I
2218 113 115 117 iii4 iii6  m il III5 III8 1111 III 13
7406 12 III1 III3 114
7409 12 III
7408 12 114 III5 112 III1
7411 112 114 III3 III7 116 III4 III9
7401 112 III2 III4 III 10 IV2 VI III7 IV9 IV10 
III 14 IV11
IV6  IV13 117 II]
1065 112 III4 III2 IV1
7403 12 116 114 III1
7413 III2 III3 III7 III6
7412 112
7319 113 III4
7402 118 III 14 III 18 III9 III 12 114 116
7407 12 III8 118 114 II14 II10 112 II12 III20 III21 III7 III 12 III 13 I] 
III14 III15 III 16
7410 III2 114 II12 III4 IV3 III8 III9 III 10 116 118 II10III7
7399 112 III8 III3 IV1 III9
7405 112 III11 III 13 IV6  IV8 III9 III4 III6  III8  IV1
TOTAL 38 19 32 2 0
TABLE 3 - O BLIGATE CARRIERS AND FEM ALES AT R ISK  OF 
CARRYING H A EM O PH ILIA  A INVESTIGATED
THE FEMALES AT RISK ARE DIVIDED ACCORDING TO CARRIER 
STATUS ASSIGNED BY THIS STUDY
L A C K  OF PA R E N TA L M A T ER N AL LACK  OF G R A N D P A R E N T S
D N A  H O M O ZYG O SITY  DNA
PEDIGREE INDIVIDUAL PEDIGREE INDIVIDUAL PEDIGREE
7406 H4 7401 IV6  7410
7401 117 7401 IV13
7401 HI12 7407 III7
7413 ni6 7407 III1 2
7402 114 7407 III 13
7402 116 7407 III22
7410 116 7407 III14
7410 118 7407 HI15




TABLE 5 - 20 FEMALES AT RISK OF CARRYING
HAEMOPHILIA A TO WHOM DNA ANALYSIS 
WAS UNHELPFUL
P E D IG R E E  IN D IV ID U A L  CARRIER PRO BE F V III:C i vW F:A g O DDS
STATUS (iu/dl) (iu/dl)
2218 III4 C IG 130 100 1:16
III6 C IG 80 125 8:1
7399 III3 c IG 110 70 1:16
7401 IV2 c IG 35 72 2:1
VI c IG 42 84 4:1
7405 III9 c EG 180 82 1:16
IV6 c IG 130 100 1:16
IV8 c IG 74 175 128:1
7407 114 c EG 19 66 8:1
II14 c EG 41 50 1:3
7411 III7 c IG 77 137 32:1
2218 III5 NC IG 140 52 1:16
7399 IV1 NC EG 110 55 1:16
7405 III4 NC EG 130 115 1:12
III6 NC EG 250 185 1:16
III8 NC EG 180 165 1:12
IV1 NC EG 180 180 1:6
7407 112 NC EG 62 41 1:16
7408 III1 NC EG 90 65 1:16
7410 III8 NC EG 100 100 1:6
III9 NC EG 110 100 1:10
III 10 NC EG 100 60 1:16
IV3 NC IG 140 72 1:16
2218 III8 NC IG 82 50 1:16
TA BLE 6  - R E SU L T S OF C O A G U L A T IO N  TE ST IN G  UPO N IN D IV ID U A L
ID E N T IFIE D  AS C A RRIER (C) OR N O N  C A R R IE R  (NC ) U SIN G  
IN T R A G E N IC  (IG ) AND EX T RA G E NIC  (EG ) P R O B E S.
THE FINAL COLUMN SHOWS THE ODDS OF THE LIKELIHOOD THAT 
THEY ARE CARRIERS FROM THE COAGULATION DATA.[Prentice et al,1975]
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Figure 4 - Pedigrees of Haemophilia A Families
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Figure 4 - Pedigrees of Haemophilia A Families
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Figure 4 - Pedigrees of Haemophilia A Families
Figure 5(a)
Intragenic RFLPs, F 8 A/Bcl I and F 8 B/Bgl I used to investigate
Haemophilia A
Factor 8  A (Exon 17-18)
Factor 8 B (Exon 26)
Figure 5(b)
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Figure 6
Non paternity demonstrated in two pedigrees: 7402 (individual IL) and 7405 (individual IIIg).
Results listed in order: F8A, F8B, D xl3, Stl4.
Figure 7
Recombination between Haemophilia A and St 14 probe in three individuals in two 
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24 wom en tested  by both coagulation m ethods and RFLP’s  for Haemophilia A. Diagram 
show s odds of carrier status derived from coagulation results and the change in odds after 
results from RFLP’s  are obtained. RFLP results from extragenic probes are plotted as 20:1 
w hereas results from intragenic probes give results of at least 1000:1
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Prenatal diagnosis in Pedigree 7319. Fetus has the allele linked with Haem ophilia 







IV.2 HAEMOPHILIA B 
IV.2i Individuals Tested
Within the West of Scotland 52 males with haemophilia B were identified with an age 
range of 2 to 76 years. This represents a prevalence of 1 in 26,900 males. Initially, 
these were considered to belong to 35 separate families but extended pedigrees reveal 
that several were related. Of the remaining 28 families, 16 contained only a single 
affected male and 12 had two or more affected subjects. Two of these 12 families were 
unwilling to participate in this study. However a further two families were referred to 
the Duncan Guthrie Institute from other centres for investigation during the course of the 
study and their results are included. A total of 128 individuals were tested of whom 30 
were obligate carrier females, 32 were females who were at risk of being earners of 
haemophilia B and 31 were affected males. The pedigrees of these families are shown in 
figure 12. The DNA results and haematological results are presented in appendix II.
IV.2ii Allele and Heterozygote Frequency
Figure 13 illustrate the RFLPs used in this study. The frequency of each allele in 
unrelated Scottish subjects is indicated in table 7.
The allele linked with haemophilia B in the families investigated is shown in table 8 . In 
the three RFLPs investigated the more common allele found in normal individuals in the 
West of Scotland was also the more common allele in disease linkage although the 
preponderance of the 11.5kb fragment in the F9(VIII)/Xmn I RFLP was higher than in 
normal subjects.
IV.2iii Female Relatives Investigated
The thirty living obligate carriers who were tested are identified in table 9. This table 
also contains details of thirty two females at risk who were tested. Eight (25%) of these 
women were shown to be carriers of haemophilia B using these recombinant DNA 
techniques whilst thirteen (41%) were shown not to be.
The data from obligate carriers and possible carriers is broken down to quantify 
homozygote and heterozygote frequency in both these groups. There is an increase in 
the heterozygote frequency for the F9(VIII)/Taq land F9(VIII)/Xmn I RFLPs in the 
possible carrier group compared to the heterozygote frequency in the healthy Scottish 
population (Tables 10 and 11).
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In these families eleven females (34%) could not be counselled as a result of DNA 
analysis. However three of these females had factor IXc levels at or below the lower 
limit of normal (normal range 50% - 200%) and had haemorrhagic symptoms (pedigree 
4549 III5: factor IXc level 52%; pedigree 4565 IV2: factor IXc level 42% and pedigree 
4555 IV4: factor IXc level 50%). Although normal coagulant studies do not exclude 
earner status of haemophilia B, the combination of clinical history and low factor IXc 
levels indicate a high probability that these three females are earners. Eight females 
could not be counselled despite DNA analysis and coagulation testing. For three of these 
females the problem is maternal non-information for the RFLPs tested (pedigree 4542 
IV 13, pedigree 4551 115 and pedigree 4551 III3) and for the other five unavailability of 
one or both parents for testing prevented interpretation of the consultand's DNA result 
(pedigree 1756 III7, pedigree 3569 114, pedigree 3569 III5, pedigree 4542 III2 and 
pedigree 4542 III3).
Thus DNA analysis alone permitted definitive genetic counselling of 21 of 31 females at 
risk (6 8 %). The addition of coagulation results allowed 24 of 31 females (77%) to be 
offered genetic counselling.
There were 38 carriers either obligate or identified by DNA analysis. Of these 28 (74%) 
were heterozygous with at least one probe and so theoretically were in a position to be 
offered prenatal diagnosis for any future pregnancy. However, only 29 of these 38 
earners were tested with all three probes. 24 of the 29 women were informative for at 
least one probe (83%), eight out of the 29 were informative with two probes (28%). 
There was no carrier female who was heterozygous with all three RFLPs.
IV.2iv Prenatal Diagnosis
In family 1756 (Fig 14) III9 underwent prenatal diagnosis after amniocentesis and a male 
foetus without haemophilia B was predicted by DNA analysis. Unfortunately this 
pregnancy was also at a 1 in 4 risk for cystic fibrosis as IV 10 is so affected. Amniotic 
fluid biochemistry and ultrasonography suggested a recurrence of cystic fibrosis which 
was confirmed at necropsy after termination of pregnancy.
R FLP
F 9(V III)/T aq  I
F9(V III)/X m n I
F 9(X III)/D d e I
POLYM ORPHIC FREQUENCY NO.OF UNRELATED








TA BLE 7 - ALLELE FREQUENCIES FOR FA CTO R IX IN TRA G EN IC 
RFLPs IN NORM AL SCO TTISH  SU BJECTS
R F L P  PO LY M O R PH IC  NU M BER  LINK ED
FR A G M EN TS W ITH
(kb) H A EM O PH ILIA  B
F9(V III)/T aq I 1.8 7
1.3 5
F 9(V H I)/X m n I 11.5 10
6.5 1
F 9(X III)/D de I 1.75 1
1.7 5
N U M B E R  OF F A M IL IE S  
IN V E S T IG A T E D
12
11
TABLE 8  - ALLELE LINKED W ITH H A EM O PH ILIA  B 

















2377 112III2 III 13 
119 IH8 IV5
IV2
3569 D2 III2 IV2 IV 3 114III5
4542 m i III7 
IV10 V3
VI ID2 III3 
IV13
4549 12 114 
116 mi III2
III6 1115*
4551 12 112114 115 III5
4555 114IV5 III6 IV4*
4559 112114 III2 III3III4
4569 IV7 VI IV2*
5215 12 114
5292 IV3 V2 V4
TOTAL 30 8 (+3 COAG) 13 11 (-3COAC
* = BY COAG CARRIER
TABLE 9 - OBLIGATE CARRIERS AND FEMALE RELATIVES AT 
RISK OF CARRYING A HAEMOPHILIA B GENE
PROBE No.TESTED HOMOZYGOUS NUMBER OF HETEROZYGOTE
ALLELES HETEROZYGOTES FREQUENCY
F9(V III)/T aq I 30
F9(V III)/X m n I 29
F9(X III)/D de I 27
I.8kb 1.3kb
7 10 13 43%
ALLELES
II.5kb 6.5kb
21 1 7 24%
ALLELES 
1.75kb 1.7kb
0 15 12 44%
TABLE 10 - HOM OZYGOTE AND H ETERO ZY G O TE FREQUENCY OF 
TH R EE INTRAGENIC RFLPs IN 30 O BLIG A TE 
CARRIERS OF HAEM O PH ILIA  B






3 5 20 71%
ALLELES 
11.5kb 6.5kb
7 0 10 58%
ALLELES 
1.75kb 1.7kb
0 6 4 40%
TABLE 11 - HOM OZYGOTE AND H ETERO ZY G O TE FREQ U ENCY  O F 
TH R EE INTRAGENIC RFLPs IN 32 FEM ALES AT R ISK  
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Three RFLPs used to investigate Haemophilia B
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IV.3 VON WILLEBRAND DISEASE 
IV.3i Individuals Tested
Thirty eight individuals from eleven different families were studied. These represented 
all the individuals registered at the Regional Haemophilia Centre who were affected by 
von Willebrand disease, had more than one individual member in their family affected 
and were willing to participate in the study. Of these eleven families, six families 
provided DNA samples from only two members and a further two families from three 
members. The pedigrees of these families are illustrated in figure 15. The complete 
DNA results obtained and all haematological results are presented in appendix III.
IV.3ii Allele Frequency
The RFLP used in this study is shown in Fig 16. Examining twenty two unrelated 
individuals the allele frequency was 0.64 for the 9kb allele and 0.36 for the 7.4kb allele. 
In this study twenty of thirty eight individuals were heterozygous. In eight families 
studied the disease was associated with the 9kb allele in six and the 7.4kb allele in two.
IV.3iii Inheritance
In 10 families autosomal dominant inheritance was apparent and in the informative 
meioses in families 7512 and 7517 there was co-segregation of the disease trait and the 
vWF polymorphism. However, in all other families the results were not informative and 
could not have been used in a predictive fashion for any future pregnancy.
IV.3iv A New RFLP
There was no evidence of gross gene rearrangements or deletions in affected individuals 
from these families but four individuals from three families showed replacement of one 
13kb invariant band by a fragment of 15kb (12 pedigree 7514, 115 pedigree 7514, 114 
pedigree 7516, III6  pedigree 7522, Fig 17). This is a further RFLP using the same 
probe and enzyme combination which will give additional information in informative 
families.
IV.3v Severe vWD
In one family autosomal recessive inheritance was suspected. The parents are Asian first 
cousins. The mother has no symptoms nor any relatives with coagulation problems, the
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father has symptoms of mild von Willebrand disease (pedigree 7517, Fig 15). Their 
eldest daughter III, has severe vWD with repeated haemorrhagic problems. A younger 
daughter and a son are asymptomatic. However as seen from the results in the appendix 
both parents and the asymptomatic daughter had haematological evidence of mild vWD. 
Fig 18 shows the results of DNA analysis in this family. Both parents are heterozygous 
for this RFLP (9kb/7.4kb). The severely affected child is homozygous for the 9kb 
fragment, the mildly affected child is heterozygous and the normal child is homozygous 
































































































































































































RFLP used to investigate von Willebrands disease.






A new RFLP with vWF/Bgl II. The 13 Kb Band thought to be constant 










Pedigree 7517. Severe vWD in II is linked with the 9Kb allele inherited from 
both parents in a consanguinous marriage. II, who has mild vWD has one 9Kb





C H A PTER  V - DISCUSSION
V .l H A EM O PH ILIA  A
V .li Allele Frequency for RFLPs
The allele frequency for the three bi-allelic RFLPs, F 8 A, F 8 B and DX13, were 
measured in individuals from the West of Scotland unaffected by haemophilia A and in 
obligate earners. The allele linked with haemophilia A was also assessed in the 16 
families tested. Table 12 compares the result of this present study with the original 
description of the RFLP by Gitschier et al [1985A] and other more recent studies.
Gitschier et al found the allele frequency in 70 haemophiliacs to be 63% for the 0.9kb 
allele and 37% for the 1.2kb allele. The report does not make clear whether all 
haemophiliacs were unrelated. However this is a larger percentage of haemophiliacs 
having the 1 .2 kb allele than would be predicted from the results of studies in normal 
individuals. This is more pronounced in the present study where the allele frequency is 
50% for each in 16 unrelated haemophiliacs. Thus both the initial report and the current 
study suggest that the 1 .2 kb allele is slightly more frequent in haemophiliacs than would 
be predicted from normal population studies. The calculated heterozygous frequency in 
the normal population in this study is 36.9% whereas the heterozygote frequency in 38 
obligate carriers is 50%. This slight increase in linkage between the less common allele 
and the disease may make this particular RFLP even more useful than initially predicted.
Separating data concerning normal unrelated individuals and data from haemophiliac 
families in published series would help to identify whether there is a difference between 
the two groups.
The initial description of the association between the probe DX13 and haemophilia A 
[Harper et al, 1984] reported that 17 of 35 normal women tested were heterozygous for 
the two alleles, 9 were homozygous for the 5.8kb band and 9 homozygous for the 2.8kb 
band. Thus the allele frequency for each band was 50%. In this study, the 2.8kb allele 
was more common. 62.5% of 48X chromosomes tested shared the 2.8kb allele. This 
was reflected in the 16 families tested for linkage with haemophilia where the 2 .8 kb 
fragment was linked with haemophilia in 1 2  of the 16 families tested. Brocker-'Vriends 
et al [1987] report a frequency of 50% for each allele in 80X chromosomes tested. 
Moodie et al [1988] found that 46% of 108 individuals from haemophiliac families were 
heterozygous but they do not give an allele frequency.
PRESENT GITSCHIER BROCKER-VRIENDS PECORARA MOODIE 
STUDY et al et al 1987 et al et al
1985A 1987 1988
N o o f  X
ch rom osom es 45 63 88 153 139
tested
N o w ith  0.9kb 34 - - - 99
a lle le
% w ith  0.9kb 75.6 79 80 65 71
a l l e le
N o w ith  1.2kb 11 - - - 40
a l l e le
% w ith  1.2kb 24.4 21 20 35 29
a lle le
C om m en ts Non- Non ?Related
Related Haemo- ?Haemo-









TABLE 12 - COMPARISON OF ALLELE FREQUENCIES OF F8A IN 
PRESENT STUDY COMPARED WITH PUBLISHED  
SERIES
PR ESEN T O BER LE JA N CO  PE C O R A R A  M O O D IE  
STU DY  et al et al et al et al
1985A 1987 1987 1988
N o o f In d iv id u a ls 35 ?
T ested
H eterozygote  83 78
F requ en cy  (% )









Obligate Obligate Non related
Carriers Carriers Individuals
of Haemo- of Haemo­
philia A philia A
+ Normal 
Women
TABLE 13 - HETEROZYGOTE FREQUENCY FOR Stl4/Taq I RFLP IN 
PUBLISHED SERIES COMPARED TO PRESENT STUDY
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Only 13 of the families in this present study were tested for linkage between the 
polymorphism and haemophilia A using probe F8B. 11 of the 13 families showed 
linkage with the 5kb RFLP and 2 showed linkage with the 20kb fragment. The 
calculated heterozygous frequency in the normal population was 31%. Antonarakis et al 
[1985A] first reported this RFLP and noted that the polymorphic Bgl I site was present 
in differing frequencies in different ethnic groups. In Mediterraneans, 90% had the Bgl 
I site giving an estimated heterozygote frequency of 18%, in Asian Indians the 
heterozygote frequency is less with 94% of the X chromosomes tested having the 
polymorphic site but in American blacks only 74% of X chromosomes had the 
polymorphic site giving a heterozygous frequency of 38%. The study by Moodie et al 
[1988] reports a heterozygous frequency of 25% in 139 unrelated X chromosomes or 
31% in 115 women being investigated as members of haemophiliac kindred. The 
figures would suggest that the probe may be slightly more useful in Britain than in the 
USA.
The S tl4  probe reveals a polymorphic system with at least 10 allelic fragments when 
digested with the restriction enzyme Taq I. The initial report of this polymorphism 
[Oberle et al, 1985A] stated that the calculated heterozygote frequency was 78% and this 
is very similar to the heterozygote frequency of 83% reported here for 35 obligate 
carriers tested with Stl4  (Table 13). The initial report of the Stl4 probe described three 
separate polymorphisms with the enzyme MspI and reported a heterozygous frequency 
of 70% for all three. Since that initial report, there has been little further work reported 
using these RFLPs. In the current study, the women tested with the MspI RFLP were 
all non informative. However these women only came from two families and were 
already shown to be non informative with the Stl4 Taq I polymorphism. There is likely 
to be strong linkage disequilibrium between these two RFLPs.
V .lii Deletions and Insertions
40 males with haemophilia A were tested. None was shown to have deletions at the site 
of intragenic probes. Allele sizes were as reported and there was nothing to suggest 
either DNA deletion or insertion as the cause of their haemophilia.
Initially, it was expected that, similar to the findings in haemophilia B, patients with an 
inhibitor to factor VIII would be likely to have a demonstrable deletion of the FVIII gene 
[Giannelli, 1983]. However, in 507 patients investigated, 19 different deletions have 
been identified but only 7 of these patients had a factor VIII inhibitor. One patient who 
apparently had deletion of the entire factor VIII gene did not develop antibodies. All 
deletions were associated with severe haemophilia apart from one reported case of a
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5.5kb deletion in exon 22 where the patient had moderately severe haemophilia 
[Antonarakis et al, 1987].
Two unrelated patients have been described with insertions in exon 14 of the factor VIII 
gene. Both patients had severe haemophilia. These insertions appear to be what are 
known as LI sequences which contain DNA which may code for a reverse transcriptase 
allowing the entire LI sequence to be inserted into DNA elsewhere in the genome via an 
RNA intermediary [Kazazian et al, 1988].
Antonarakis et al [1987] point out that 4-5% of families tested will show a detectable 
deletion if probed with the whole factor VIII gene and recommend that this be done 
routinely when investigating for carrier detection or pre-natal diagnosis. It is unlikely 
that this will be done routinely in all families, however it is another approach to 
investigation which is available and may be particularly useful if RFLPs are not 
informative, if paternal DNA is unavailable or if pre-natal diagnosis would otherwise 
depend upon extragenic probes.
V .liii Carrier Detection
The present study found that 51/71 females (72%) at risk of being a carrier for 
haemophilia A could be advised about carrier status on the basis of information obtained 
from at least one of the four RFLPs used. Only 41% could be advised from information 
obtained from intragenic probes and the rest relied upon extragenic probes.
The initial reports of the four probes all described the application of the probes to carrier 
detection although these reports often dealt with small numbers. Gitschier et al [1985A] 
mentioned carrier detection in only one female, Antonarakis et al [1985A] in five out of 
six families informative for either the Bel I or the Bgl I polymorphism although this 
paper gave no results for the carrier studies. Winter et al [1985] reported results of 
earner detection in nine women from six families whilst Oberle et al [1985B] reported 
carrier detection in three women at risk of being carriers.
Subsequent reports examined larger groups of women. Early in 1986, a report appeared 
from Janco et al investigating families with the same four probes used in this study. 
They looked at "over 34" obligate carriers in 29 families. The heterozygous frequencies 
were similar to the present study with 92% heterozygous for Stl4, 37% with F8B, 35% 
DX13 and 65% F8A. They also looked at DNA probe combinations and in 24 obligate 
earners studied there was a 100% heterozygote frequency when a combination of S tl4  
and F8A were used. This fell to 68% when the combination was F8B and F8A. They
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were also able to assign carrier status in seven female relatives but did not say how large 
the group of females at risk was. The conclusion of this report was that the most 
efficient strategy for carrier testing would be to use both St 14 and F8A probes to identify 
heterozygosity.
The theme of identifying an efficient carrier strategy was picked up in a short report 
[Intrator et al, 1987] from France. In 23 families only 40% of obligate earners were 
informative for F8A and 26% were informative for F8B. However there was strong 
linkage disequilibrium between the two probes such that there was no additional 
information generated by the use of F8B. A much larger study from Italy reported at the 
same time [Pecorara et al, 1987] investigated 61 haemophilia A families. 350 relatives as 
well as 61 haemophiliacs were investigated using three gene probes F8A, St 14 and 
DX13. In obligate carriers, 30% were informative for F8A, 82% Stl4  and 60% DX13. 
Laboratory results for S tl4  and F8A showed 91% of obligate carriers to be 
heterozygous. When the three probes were combined, 23 of 24 (96%) of obligate 
carriers were informative. When investigating carrier detection, the families were 
divided into 27 families with at least two haemophiliacs in different sibships "the 
inherited cases" and 34 families with one or more haemophiliacs in only one sibship "the 
sporadic cases". Whilst this division may not be absolutely correct, it reflects the 
pragmatic approach which is likely to be taken when haemophiliacs and their families 
present to a genetics out-patient clinic. In the inherited group studied, there were 29 
women at risk and all could be assigned carrier or non-carrier status from these studies. 
In the sporadic cases, 45 women were investigated. 6% of these families were non- 
informative. The studies of sporadic cases also depended upon abnormal maternal 
clotting studies to classify the mother as a carrier before DNA studies could be used to 
establish the carrier status of the daughter. It is interesting to note that in this large Italian 
study, the haemophiliac families appeared to be less informative with the F8A probe than 
in previous studies.
Brocker-Vriends et al [1987] reported a high earner assignment rate. 52/57 women 
tested could be informed of their carrier status. This did not state how many women 
depended upon data from extragenic probes alone. A more recent report of carrier 
assignment in 100 potential earners [Moodie et al, 1988] reported a 73% carrier 
assignment rate which is very similar to the present study. 21% of carriers depended 
upon data from extragenic probes.
The clinical usefulness of data relying upon extragenic probes alone has come to be 
questioned as it has become apparent that there is a significant crossover frequency 
between the extragenic RFLPs and the haemophilia A gene.
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V .liv  Genetic Crossover
In this study, no evidence was found of genetic cross-over between the disease trait and 
the two intragenic probes, nor between the gene for haemophilia A and DX13. However 
the recombination rate between Stl4 and haemophilia A in this study was 10.7%.
At the time that extragenic or linked probes for haemophilia A were first described, it 
was recognised that there was at least a theoretical possibility of crossover between the 
polymorphic probe site and the gene for haemophilia A. The original description of 
DX13 [Harper et al, 1984] observed no cross-over however. Winter et al [1985] 
described recombination between DX13 and F8A in one woman and calculated that the 
recombination fraction was 5%. Peake et al [1985] quoted a recombination fraction of 
8% for the same probes. Initial reports of investigations with St 14 suggested that 
recombination was rare. Oberle et al [1985A] found no recombinants in 57 meioses 
between the St 14 locus and the gene for factor VIII and the initial prediction by Janco et 
al [1986] was that it would be less than 1.5%. Peake et al [1986] estimated that it was 
4.5%. However at the same time, a group from Finland reported two recombinations in 
27 meioses [Lehesjoki et al, 1986] and a further recombination was reported by Driscoll 
et al [1986] suggesting that the recombination rate was higher than initially predicted. 
One of the families investigated by Lehesjoki showed recombination between S tl4  and 
FVIII and also between DX13 and FVIII suggesting that S tl4 and DX13 both lay on the 
same side of FVIII rather than flanking the haemophilia A gene. Brocker-Vriends et al
[1987] also reported one recombination of Stl4 and haemophilia A which also showed a 
recombination between the DX13 and the haemophilia A locus - again supporting the 
hypothesis that the two probes are juxtaposed on one side of the haemophilia A gene. 
The recombination frequency for the two probes reported by this group was 3.9% 
between Stl4 and haemophilia A and 5% between DX13 and haemophilia A.
The position of these two probes was of some importance since flanking probes would 
have been more useful. Recombination would be less likely to result in recombination of 
both probes if they were flanking the gene of interest rather than juxtaposed on one side. 
However for a long time, the order of the probes in relationship to the genes at the tip of 
the X chromosome was disputed. Using somatic cell hybrids, Tantravahi et al [1986] 
placed DXS15 (DX13) and DXS52 (Stl4) distal to F8 giving the order centromere - F9- 
F8 (DXS15, DXS52) - telomere. However data from Mulligan et al [1987A] disputes 
this and suggests the most probable order as centromere - fra(X) - DXS15 - DXS52 - F8 
- telamere. Mulligan et al suggest from their data that the recombination rate is between 3 
and 5% between Stl4 and FVIII. This is considerably less than the present study where 
three recombinations were observed in 28 informative phase known meioses (10.7%)
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between S tl4  and F8C. Clearly this is affected by the fact that two of the recombinants 
were in one family. It has been suggested that some families may be more predisposed 
to genetic recombinations in this area and until these studies are performed within each 
regional population, it will not be possible to say how variable the recombination rate 
may be. This information is important to genetic counsellors. If there does prove to be a 
regional or inter family variation in the recombination rate then the present system of 
collecting national and international data may produce misleading guidelines.
It is estimated that the recombination frequency of 1% is thought to average about 1000 
kilobases of DNA [Graham et al, 1985]. Thus even a very long gene such as that coding 
for factor VIII which is 186kb in length is very unlikely to show recombination between 
the site for haemophilia A and the sequences detected by an intragenic RFLP.
V .lv  Coagulation Testing
As discussed in the introduction to this study, coagulation tests have been the most 
important method of identifying carriers amongst women at risk prior to the introduction 
of recombinant DNA technology. They will continue to be important in centres where 
DNA probes are not available in families not informative for available probes, in mid 
trimester foetal blood sampling or in families where information is only available for 
extragenic probes. The effect of lyonisation has been known to render interpretation of 
results difficult since coagulation tests for potential earners were first described [Lyon, 
1962]. It is not tenable that lyonisation will cause abnormal coagulation in a normal 
female however the reverse situation is widely recognised and accepted as a common 
cause of mis-classification of females at risk. In this study, 24 women at risk were 
tested with coagulation studies and DNA techniques. The coagulation studies were not 
optimum as many women only had them done on one occasion. The current 
recommendations are that these are repeated at different times to elicit day to day 
variability in results and maximise the detection rate for carriers of haemophilia A 
[Rapaport et al, I960]. Nevertheless, the results are valid as they stand although 
repeating tests may have improved the carrier detection rate.
13 of these women were assigned non-carrier status from the DNA probe results 
although only three of these were assigned from data obtained from intragenic probes. 
In all 13 non-carriers, the coagulation data supported the results of the DNA studies and 
using the chart illustrated in the paper from Prentice et al [1975] the odds were against 
these women being carriers. In this group of women, particularly when relying upon 
extragenic probes alone, coagulation data may be used to support the DNA studies and 
vice versa. Since lyonisation in a non-carrier will not produce abnormal coagulation, an
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abnormal coagulation result which fell within the area suggesting carrier status in a 
woman where results of extragenic probe suggested non-carrier status would cause one 
to look veiy hard for recombination, mixed samples, non paternity 01* any other cause of 
error in DNA techniques. It would therefore seem prudent in this situation to continue to 
use both techniques.
11 women were assigned as carriers using DNA probes. In 8 women, the data was 
obtained from intragenic probes which is regarded as highly reliable. In 3 of these 
women where data is believed to be highly reliable, coagulation studies produced odds 
of carrier status of 1:16. This figure is derived from an illustration in the study of 
Prentice et al [1975] and 1:16 are the highest possible odds. The 3 women who were 
assigned as carriers using extragenic probes were assigned as non-carriers by 
coagulation testing in 2 cases. 1 had odds of 1:16 whereas the other was only 1:3. This 
data highlights two possible problems. In women assigned carrier status with intragenic 
probes where the coagulation data conflicts with this, one would be inclined to put more 
reliance on the DNA studies. One would, however, have to exclude non paternity as a 
cause of unreliable data and also simple laboratory error such as mislabelling of samples. 
The second area can be checked easily by repeating the test and paternity testing has 
become simpler with the introduction of hypervariable mini satellite probes [Jeffreys et 
al, 1985]. The difficulty increases in women assigned as carriers with extragenic probes 
where coagulation testing suggests non-carrier status. Simple measures such as 
repeating tests 01* excluding the possibility of non-paternity may decrease the number of 
women where this conflict exists but is unlikely to remove the problem. Further studies 
among female relatives may detect coagulation abnormalities associated with the same 
extragenic allele but this would not exclude cross-over between the disease locus and the 
gene for factor VIII:C in the women being tested.
V .lv i Prenatal Diagnosis
During the time of this study, only one woman requested early prenatal diagnosis by 
chorionic villus sampling as she did not wish to have a haemophiliac child. (Another 
patient, discussed in the Haemophilia B section had mid trimester diagnosis). The 
woman in this family (Pedigree 7319) had one haemophiliac brother and was an obligate 
carrier as she had already had a fetus diagnosed as haemophiliac in mid trimester by 
foetal blood sampling. This resulted in a mid trimester termination of pregnancy which 
the family were anxious to avoid on this occasion. The woman presented as a new 
referral to the Genetics Institute at eight weeks gestation which meant that chorionic 
villus sampling and DNA analysis had to be arranged rapidly. Whilst this particular 
family were both highly motivated and well informed prior to referral nonetheless some
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very rapid decisions had to be made at a very emotional time for parents. By using 
RFLPs to detect earners prior to pregnancy it would be hoped that they would have 
discussed prenatal diagnosis prior to pregnancy. That the family preferred to have early 
trimester diagnosis and termination if necessary rather than mid trimester did not seem 
surprising and indeed the assumption that women would prefer early diagnosis and 
termination if this is necessary has been supported by a recent study [Spencer and Cox,
1987]. Nonetheless the risk to the pregnancy is now accepted at 2-4% [Ward, 1987] 
which is probably twice the risk of amniocentesis even when the inevitable losses up to 
16 weeks are excluded. Transcervical chorionic villus sampling is more likely to result 
in infection or bleeding than the transabdominal route. Both may cause Rhesus 
sensitisation [Jackson and Wapner, 1987]. A recent randomised study comparing 
transcervical chorionic villus sampling (CVS) with amniocentesis has shown a higher 
perinatal mortality in the CVS group with crude perinatal mortality rates of 1.3% and 
0.6% respectively [Canadian Collaborative CVS-Amniocentesis Clinical Trial Group,
1989]. There is also concern that maternal contamination may confuse results. In 
particular techniques using PCR to amplify DNA may cause more problems with 
maternal contamination [Craig et al, 1989].
V .lv ii Linkage between G6PD and Factor VIII Genes
It is widely accepted that the G6PD gene and the gene for FVIII lie closely together and 
linkage can be sought when there is an abnormality detectable in both. McCurdy in 1971 
reported carrier detection for haemophilia A using an electrophoretic heterogeneity of 
G6PD seen in American negroes. He also suggested that the same techniques could be 
used for prenatal diagnosis since determination of the G6PD phenotype is possible from 
about 10 weeks gestation. A recent report by Filippi et al [1984] brought to a total of 58 
the number of scorable siblings and non-recombinants recorded in the literature for the 
linkage Haemophilia A - G6PD.
In the present study, one family (Pedigree 7409) had two haemophiliac sons who were 
also G6PD deficient. Their sister was assigned a carrier from results obtained using the 
RFLP detected by S tl4  and was also shown to be heterozygous for G6PD deficiency. 
In this family, linkage is maintained between haemophilia A, G6PD deficiency and St 14. 
It is useful to have further confirmatory evidence of carrier status when using extragenic 
probes. At present, the ordering of these probes in relationship to the two genes is 
uncertain. It would be particularly useful if S tl4  and G6PD flanked on either side of 
haemophilia A. The G6PD gene has also been sequenced [Martini et al, 1986] and it 
may be that intragenic RFLPs from that gene may be as useful as S tl4  or DX13 in 
carrier detection for haemophilia A.
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V .lv iii Linkage between Colour Blindness and Factor VIII Genes
Linkage between the genes for red/green colour blindness and haemophilia A has been 
long established [Haldane and Smith, 1947]. When both diseases occur in the same 
family, it is occasionally possible to use colour blindness as a linked marker for carrier 
detection in the same way as extragenic RFLPs are used although it is associated with the 
same problem of the possibility of genetic cross-over.
There are two genes involved in red/green colour blindness, lying adjacent to each other 
on the X chromosome. One codes for red pigment and the other for green pigment. 
They each consist of six exons but have 96% homology with each other. It is thought 
that this extensive homology promotes misalignment of gene sequences resulting in 
unequal crossing over which may cause fusion gene products or gene duplication and 
deletion. About 8% of men have some form of red/green colour blindness [Lancet,
1990].
Kenwrick and Gitschier [1989] have produced a physical map of Xq28 using pulsed 
field gel electrophoresis and have shown that the genes for red/green colour blindness lie 
on the opposite side of the factor VIII gene to DX13 and Stl4. In the family presented 
in this thesis with both diseases, earner detection for haemophilia A depended upon 
information from the extragenic probes DX13 and St 14. Any complementary 
information obtained by following the gene for colour blindness through the family with 
no evidence of genetic cross over would enhance the information from the extragenic 
probes alone. In this family, the gene for colour blindness appeared to derive from II. 
Consequently, all his daughters will be obligate earners of this disorder. 118 is an 
obligate carrier of haemophilia A with an affected son III 11 who is not colour blind. 
Since the colour blind gene and the haemophilia A gene lie on different X chromosomes 
in this individual, it might be possible to use colour blindness as a linked marker. 
Assuming that 117 (husband of 118) is not colour blind then, in the absence of genetic 
cross over, a daughter inheriting the gene for colour blindness will not be a carrier of 
haemophilia.
The low lod score calculated between colour blindness and DX13 or S tl4  reflects the 
fact that there were only a small number of individuals in one pedigree with appropriate 
data. However, since lod scores can be added between pedigrees, it is data worth 
accumulating as the genetic distance between colour blindness and DX13 or S tl4  can be 
estimated when further pedigrees are analysed.
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V.2 HAEMOPHILIA B 
V.2i Allele Frequency for RFLPs
The 3 RFLPs which were used were the only 3 available at the time that the study was 
undertaken. The allele frequencies obtained in this study are compared to those 
originally published and subsequent series and are shown in Table 14.
The allele frequencies of the 3 RFLPs in this study were strikingly similar to those 
reported by the authors who identified them [Giannelli et al, 1984; Winship et al, 1984] 
although it has been suggested that allele frequencies may vary between different white 
ethnic groups [Hassan et al, 1985]. The relative increase in the percentage of 
haemophilia B families in this study showing association with the more common Xmn I 
polymorphism is interesting to note (10 out of 11 families) and does not reflect the 
frequency of this allele in the normal Scottish population which was found to be 0.68. It 
is however consistent with the finding that only 24% of obligate carriers from these 
families were heterozygous for this particular RFLP. In these small numbers it can only 
be speculation whether this reflects a common ancestral pool although the other 
genotypic differences between families would suggest that this is not the case.
These were the 3 RFLPs used to investigate families in this study. Subsequent to this 
other RFLPs have been described. Camerino et al [1985] described an RFLP detected 
using a partial cDNA probe and the enzyme MspI. The frequency of the minor allele 
was 0.20 with an estimated heterozygous frequency of 0.32. The MspI RFLP was 
found to be in strong linkage disequilibrium with the Taq I RFLP, thus limiting its 
usefulness. On the other hand the Bam HI polymorphism described by Hay et al [1986] 
gave a low estimated heterozygous frequency of 11% but showed a lack of linkage 
disequilibrium between it and the Taq I and Dde I polymorphic loci. A second Bam HI 
polymorphism was subsequently identified and found to be within 500bp 5' of the Xmn 
polymorphic site. Interestingly this gave a minor allelic frequency of 0.13 in American 
blacks but no polymorphism was identified in an American white population [Driscoll et 
al, 1988]. Other authors have also identified differences in allelic frequencies for RFLPs 
in different racial groups emphasising the importance of identifying the useful RFLPs for 
different populations [Reiner et al, 1990; Kojima et al, 1987; Lubahn et al, 1987].
V.2ii Carrier Detection
The thirty obligate carriers and thirty two females at risk are identified separately in the 
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information generated has different applications. With obligate carriers the applicability 
of these techniques is to identify those with heterozygote RFLPs who could be offered 
early pre-natal diagnosis following chorionic villous biopsy whereas with women at risk 
carrier status may be identified by RFLP analysis. Those who are identified as earners 
may subsequently request pre-natal diagnosis. The relatively high heterozygote 
frequency recorded amongst the thirty two women at risk is fortuitous (71% were 
heterozygous with the F9VIII/Taq I RFLP) and might imply that there would be an 
increased chance of offering PND. However only 8 of these 32 women were found to 
be carriers and only 2/8 of women identified as carriers were tested with all 3 RFLPs 
(both of whom were polymorphic with at least 1 RFLP) and so this cannot be stated 
categorically.
DNA analysis alone permitted definitive genetic counselling of 21 of 31 females at risk 
(68%). Using only results of Taq I RFLP then 15 of 31 females at risk (47%) could 
have been counselled. So adding two further RFLPs to the investigation panel has only 
increased the total informativeness by 21% despite the fact that in the noimal population 
of this area the Xmn I RFLP has a heterozygous frequency of 43% and the Dde I RFLP 
has a heterozygote frequency of 35% whilst in the obligate carriers tested these figures 
were 24% and 44% respectively. The phenomenon whereby less additional information 
is generated by additional RFLPs than would be anticipated by the heterozygous 
frequency is known as linkage dysequilibrium. In general teims this can be explained as 
occurring when an allelic marker is found to be close enough to another gene to be co­
inherited at greater than random frequency. In the case of RFLPs this means that the 
various alleles associated preferentially with one another in the general population to 
form a frequently occurring haplotype. Thus adding a second RFLP after testing with 
one is likely to be less useful than would be anticipated from the calculated individual 
polymorphic frequencies. Interestingly Driscoll et al [1988] reported that less linkage 
dysequilibrium was noted between Taq I and MspI polymorphic sites in North American 
Negroes compared to the North American white population. Racial differences make it 
important for each population to ascertain their own degree of linkage dysequilibrium.
Results of large series which have been published largely reflect the experience in 
Glasgow. Lehesjoki et al [1990] investigated 19 of the 20 known Finnish families with 
haemophilia B. The allele frequencies for the three RFLPs did not differ significiantly 
from the original studies. Assignment of carrier status could only be achieved in 19 of 
39 females tested (49%). However this figure included female relatives of sporadic 
cases of haemophilia B.L If these were excluded then the figure became 16 of 25 or 64% 
which is very close to the figure reported in the present study of 68%. Brocker-Vriends 
et al [1985] using only the Taq I RFLP assigned carrier status in 16 out of 19 potential
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carriers from 4 kindred (82%). Lillicrap et al [1986] using the Taq I and Xmn I RFLPs 
assigned earner status in 5 out of 14 potential earners (36%) from four informative 
kindred. With such small numbers of informative kindred it is not possible to state 
whether these differences reflect true differences in these populations.
V.2iii Gene Deletions
Amongst the 31 patients from 12 families tested with RFLPs there was no evidence of 
absent bands or alterations of fragment size to suggest gene deletion. Large gene 
deletions have been described. These are commonly, although not invariably, associated 
with patients who have circulating factor IX antibodies known as inhibitors. Giannelli et 
al [1983] investigated 6 individuals with factor IX antibodies, two of whom were 
related, to see whether there was an association between antibody production and gene 
deletion. 5 of the individuals had evidence of a deletion ranging from 9kb to greater than 
18kb. Interestingly two patients from the same kindred had evidence of different 
deletions. Since then further isolated individuals with gene deletions have been reported 
[Bernardi et al, 1985; Hassan et al, 1985; Peake et al, 1984] including one family 
investigated with three children who had haemophilia B with no evidence of inhibitor. 
They were found to have a relatively small deletion of 2.8kb around exon d and the 
surrounding flanking regions. This affected the Taq I polymorphic site and was an 
unexpected finding when pre-natal diagnosis was requested [Vidaud et al, 1986].
V.2iv Prenatal Diagnosis
During the course of this study only 1 woman (Ped 1756 III8) requested pre-natal 
diagnosis. This was a double diagnostic investigation since the woman was an obligate 
carrier for Haemophilia B and also had a 1 in 4 chance of having a child with cystic 
fibrosis. At that time in 1986 RFLPs were not available for the diagnosis of cystic 
fibrosis and so the diagnosis of CF was reached by a combination of amniotic fluid 
biochemistry and ultrasonography. CF was confirmed at necropsy. Cells obtained at 
amniocentesis were cultured to provide sufficient material for DNA extraction and, using 
the Taq I/F9(VIII) polymorphism, a male foetus without haemophilia B was predicted. 
Had it not been that at that time CF could only be reasonably predicted following 
amniocentesis then chorionic villous biopsy would have been used to obtain material for 
DNA extraction.
Compared to the situation with Haemophilia A the alternative method of PND by factor 
IX assay of fetal blood is less straightforward. In common with other Vitamin K 
dependent clotting factors the level of Factor IX remains low until the end of the
59
gestational period and into the perinatal period. This fact makes the interpretation of very 
low levels of factor IX obtained in mid-trimester more difficult than is the case with 
factor VIII [Mibashan et al, 1979]. Moreover a significant level of Factor IX is present 
in amniotic fluid. Any contamination of a fetal blood sample may thus falsely elevate a 
low level of factor IX [Thompson, 1984]. More individuals with haemophilia B have 
disproportionately high levels of factor IX antigen than is the case with haemophilia A. 
In one study over half of the haemophilia B patients had at least lOu/dl circulating factor 
IX antigen [Thompson, 1982].
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V.3 VON WILLEBRANDS DISEASE 
V.3i Allele Frequency and Linkage
The probe used in this study is an llOObp Pst I fragment of cDNA isolated by Verweij et 
al [1985B]. At the time of this study, this was the only probe available to identify 
RFLPs. The allele frequencies of 0.64 and 0.36 found in this study corresponds closely 
to the original reported frequency of 0.69kb for the 9kb fragment and 0.31 for the 7.4kb 
fragment. A heterozygous individual may not be informative when the disease in 
question is autosomal dominant. Depending upon the results of the individuals partner 
linkage may be difficult to establish when there is limited family data and only one 
RFLP. The sequencing of the cDNA has enabled partial length cDNA probes from the 
entire length of the vWF gene to be developed. These can be used either to detect gene 
deletions and insertions or to recognise RFLPs. Many RFLPs have now been described 
[Verweij et al, 1985B; Nishino et al, 1986; Quadt et al, 1986; Bernardi et al, 1987; 
Iannuzzi et al, 1987; Konkle et al, 1987; Lavergne et al, 1987; Lavergne et al, 1988; 
Lindstedt et al, 1989A; Marchetti et al, 1989; Ewerhardt et al, 1989; Lindstedt et al, 
1989B; Inbal et al, 1989]. The clinical applicability of some is very limited because of a 
low polymorphism frequency. Also there is strong linkage disequilibrium between 
many of the RFLPs making the cumulative benefit of several RFLPs less than might be 
anticipated.
The fact that linkage is established in this study as well as other studies supports the 
observation of Verweij et al, [1988], that vWD is likely to be due to a variety of 
intragenic defects rather than an abnormality of post translational processing.
The observation that the disease is linked to either RFLP allele in the anticipated ratios 
shows that neither allele is particularly linked with the disease. Also there is no evidence 
that all families tested have a common ancestry.
V.3ii Carrier Detection
In only two out of ten families with autosomal dominant von Willebrands disease were 
there informative meioses allowing the RFLP allele linked with the disease trait to be 
identified. The pedigrees in this study however were small. Carrier detection is a 
misleading term in autosomal dominant diseases where the individual with the disease 
trait manifests symptoms. Normally affected individuals would be identified by 
coagulation tests although RFLP analysis would be possible in informative families. 
Bernardi et al [1987] used four different RFLPs to investigate vWD and estimated that
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there was a 70% chance that a subject would be informative for at least one. Combining 
two RFLPs in a large family with type Ha vWD increased the informativeness of the 
analysis despite linkage disequilibrium between the two RFLPs [Verweij et al, 1988]. 
Bahnak et al [1988] also demonstrated how combined data from two RFLPs was 
important in a large family which contained one member with severe (type III) vWD.
V.3iii Gene Deletion
There was no evidence of any gene deletion detected by this particular RFLP. Only 1 
gene deletion has been described in an individual who had vWD which was not severe 
[Bernardi et al, 1990] and most others investigating type I or type II vWD have 
concluded that the disease in its mild autosomal dominant form is likely to be due to a 
point mutation rather than a deletion or insertion in the vast majority of patients.
Homozygous gene deletions have been described in patients with severe recessive type 
vWD and heterozygous deletions have been detected in their earner relatives. Gene 
deletions would appear to correlate with the development of allo-antibodies in vWD. 
However, in one study described, 19 individuals with severe vWD were investigated, of 
whom only two had detectable gene deletions. These two individuals both had 
alloantibodies to vWF. The 17 without detectable deletions did not have antibodies. The 
molecular mechanism underlying severe vWD in patients without a detectable gene 
deletion is unknown [Shelton-Inloes et al, 1987B; Ngo et al, 1988].
V.3iv Severe Von W illebrands Disease
The one family with severe vWD studied with this RFLP had no evidence of gene 
deletion. The alleles were the same size as those individuals with autosomal dominant 
vWD or unaffected individuals. The child with severe vWD is homozygous for the 9kb 
fragment. Since the parents are first cousins, it is most likely that the severe vWD is due 
to the same defect in each chromosome. That is that she is a homozygous rather than a 
double heterozygote. The linkage of the disease with the 9kb fragment in this family is 
further confirmed by the evidence of mild vWD in the heterozygous sib and no evidence 
of vWD in the child homozygous for the 7.4kb fragment.
In this study it would be possible to offer PND for any further pregnancies. 
Furthermore in a family where consanguinous marriage is likely it may be helpful for the 
affected girl and heterozygous sister to have DNA testing available either for carrier 
detection of a related spouse or PND of any pregnancy when they themselves come to 
marry and conceive.
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Bernardi et al [1988] investigated four unrelated individuals with type III vWD using 
four different RFLPs. Two of these individuals were homozygous for all four probes 
and the authors conclude that these two people are likely to be homozygous for a 
particular gene defect whereas the other two individuals who are not homozygous for the 
RFLPs they conclude are more likely to be double heterozygotes. The family of one 
individual with severe vWD were investigated by Bahnak et al [1988] using two 
informative RFLPs from which they were able to establish linkage and identify carriers 
for severe vWD. Ten affected individuals from six families were reported by Ngo et al
[1988] who divided them into three groups after studies with cDNA vWF probes. The 
first group consisted of a family with complete homozygous deletions of the vWF gene 
in the four probands. Gene dosage analysis was consistent with heterozygous deletions 
in both asymptomatic parents and four asymptomatic siblings. The second group 
comprised a family in which there was a complete heterozygous deletion of the vWF 
gene in the proband and one asymptomatic parent, suggesting that a different type of 
genetic abnormality was inherited from the other parent and the affected individual was a 
double heterozygote. In the third group, no gene deletion could be detected. 
Alloantibodies developed only in the kindred with homozygous deletions.
V.3v A Further RFLP
The 15kb band present in the autoradiograph of four individuals was associated with a 
less densely staining 13kb constant band compared to other individuals suggesting that 
in some individuals the 13kb band is not constant. A polymorphism resulting in loss of 
the restriction enzyme site which normally produces the 13kb band results in the larger 
15kb fragment being present. A personal communication with Verweij et al who first 
described this RFLP has confirmed this observation although in their population it was 
not common. Numbers of unrelated individuals studied are too small in this study to 
calculate allele frequencies. In only one family is it possible to observe inheritance. 
However the 15kb band was present in three out of eleven families investigated. A 
further polymorphism with the same enzyme and probe would clearly be useful in 
linkage studies within families. These preliminary results show this polymorphism to be 
present within four individuals of the thirty eight studied. Thus in this particular 
population it may provide useful further linkage data in a larger pedigree.
V.4 NEW DEVELOPMENTS IN MOLECULAR BIOLOGY
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There can be little doubt that the developments in molecular biology have accelerated the 
learning about disease processes, not only in genetics and haematology but in all medical 
disciplines. Identifying molecular defects fundamental to the cause of a disease is 
becoming increasingly straightforward and commonplace. New concepts of disease 
aetiology such as oncogenes and tumour suppressor genes have been introduced 
[Cooper, 1991; Mitchell, 1991]. Improved methods for identifying minimal residual 
disease in malignancy using molecular techniques have been described [Neale et al,
1991].
Parallel developments in protein biochemistry and molecular biology have resulted in a 
rapid increase in knowledge and understanding of the pathological processes which 
cause the common inherited coagulation disorders. The polymerase chain reaction 
(PCR) which allows rapid amplification of short segments of DNA has revolutionised 
the field of molecular biology opening the way to subsequent techniques of improved 
DNA sequencing, new methods of earner detection and point mutation identification 
within the field of inherited coagulation diseases [Saiki et al, 1985; Kogan et al, 1987]. 
Beyond this its scope is enormous, with PCR applications being identified in all areas of 
biological research.
V.4i Haemophilia A
The factor VIII gene is 186kb long and consists of 26 exons with 25 introns. The 
coding DNA is approximately 9kb with codons for a polypeptide of 2351 amino acids. 
The nucleotide sequences of the coding region, promoter elements and splice junctions 
have been determined.
Post translational modifications including glycosylation results in a mature single chain 
factor VIII protein of 2332 residues made up of three types of domain: A, B and C. 
There are three A domains with B occurring between the second and third and two C 
domains. The two specific thrombin cleavage sites which produce an active cofactor lie 
between the first two A domains, Arg 372 - Ser 373 and the carboxy terminus of the B 
domain Arg 1689 - Ser 1690. This second site is cleaved by thrombin activation and 
factor VIII exists as a two chain molecule in the circulation. Site specific mutagenesis 
has shown that loss of either of the thrombin binding sites affects clotting whereas the 
majority of the B domain which makes up half the mature protein can be removed 
without any effect upon blood clotting. Arg 336 - Met 337 is the cleavage site for
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inactivation of activated factor VIII by activated protein C. Immunological studies using 
antibodies to synthetic peptides to identify presumptive epitopes have allowed some 
interpretation of three dimensional structures of the molecule. Epitopes for alloantibody 
inhibitors frequently localise to the A-2 and C-2 domains [Thompson, 1990],
Knowledge of the DNA sequence and the PCR method made examining small areas of 
the FVIII gene for point mutations much simpler. The sites of thrombin cleavage or 
protein C cleavage were early targets in the search for specific point mutations which 
caused haemophilia A. Gitschier et al [1988],by screening amplified DNA with 
discriminant hybridisation of oligonucleotides, identified 2 cleavage site mutations in 215 
patients, one a nonsense mutation in the activated protein C cleavage site and the other a 
mutation resulting in a substitution of cysteine for arginine at amino acid 1689. It had 
already been predicted that the haemophiliacs with a high new mutation rate and a 
variable clinical presentation were likely to be associated with many different molecular 
defects. Kogan and Gitschier [1990] screened 228 haemophilia A patients with 
denaturing gradient gel electrophoresis (DGGE) and identified two further mutations 
around the A-2 and C-2 domains which are the neutralising anti-factor VIII antibody 
epitopes as well as a new polymorphism in intron 7. Rescreening the same population 
by making heteroduplexes between haemophiliac and normal DNA prior to 
electrophoresis revealed a further missense mutation. Schwaab et al [1991] identified 
two missense mutations in 441 unrelated haemophiliacs by investigating the thrombin 
cleavage sites by oligonucleotide screening, DNA amplification and direct sequencing. 
Other authors have also described mutations at the thrombin cleavage sites [Pattinson et 
al, 1990; Shima et al, 1989; Arai et al, 1990].
Gitschier et al [1985B] found that the restriction enzyme Taq I (recognition sequence 
TCGA) detected point mutations in the factor VIII gene of four out of 92 haemophilia A 
patients. Youssoufian et al [1987] provided evidence for recurrent mutations due to CG 
-> TG transitions at identical sites in the factor VIII gene. Further examples of recurrent 
mutations have since been found in five different Taq I restriction sites within exons 18, 
22, 23, 24 and 26 [Antonarakis et al, 1987; Levinson et al, 1990]. One mutation has 
been described in exon 26 where a mutation converts a CGA (arginine) codon to a TGA 
(stop) codon resulting in severe haemophilia. However a C-T transition in the reverse 
complement strand of DNA at the same codon in a different patient results in a 
conversion from CGA (arginine) to CAA (glutamine) and this produces only mild 
haemophilia [Gitschier et al, 1986]. The CpG dinucleotide is a hotspot for mutation 
within the human genome because it is the preferred site for cytosine methylation. 
5'methyl cytosine is prone to mutate to thymidine by deanimation. Within the factor 
VIII gene there are 70 CpG sites of which only 7 are Taq I restriction sites [Pattinson et
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al, 1990]. PCR has allowed the screening of CpG sites which are not restriction sites to 
identify further mutations. 16 patients out of 793 unrelated haemophiliacs were shown 
to have point mutations consistent with 5'methylcytosine deamination by Pattinson et al 
[1990]. Millar et al [1991] identified two C -> T transitions by screening intragenic CpG 
sites in haemophilia A patients.
Naylor et al [1991] have recently described a method for screening the active coding 
sequence of the factor VIII gene, as well as its promoter and polyadenylation regions by 
a combination of PCR techniques and screening for mutations by the amplification 
mismatch detection method which uses chemical cleavage to detect mismatches. If this 
method proves to be sensitive in a large study of haemophilia A patients it may allow the 
molecular defect in the majority, if not all, of haemophilia A families to be identified.
These new methods, once developed, can also be applied to carrier detection and prenatal 
diagnosis. Amplification of RFLP sites by PCR allows more rapid analysis in women 
who are informative [Lavergne et al, 1991] although it is now appreciated that an internal 
control of enzyme digestion is necessary to avoid misinterpretating incomplete enzyme 
digestion as an absent restriction site [Sampietro et al, 1990]. PCR amplification allows 
carrier detection from samples other than blood, such as sputum, urine and hair follicles 
which is clearly useful where blood samples are difficult to obtain [Ball et al, 1990]. 
Methods currently being described which identify point mutations in a haemophiliac are 
of particular interest to the 30% of families where there is no family history and carrier 
detection by RFLP analysis is usually unhelpful. The point mutation identified in the 
affected male can then be looked for in all women at risk of being carriers and allow 
direct carrier detection and prenatal diagnosis.
V.4ii Haemophilia B
The shorter factor IX gene of approximately 33.5kb with 3kb of sequencing genome 
was sequenced fully before the factor VIII gene. The structure of the factor IX protein is 
described in the introduction section of this thesis. Post-translational modification 
consists of cleavage of the signal peptide and propeptide followed by glycosylation and 
modification by a vitamin K dependent carboxylase of the amino-terminal Glu residue to 
form the dicarboxylic Gla form which is associated with calcium binding. Activation of 
factor IX is calcium dependent and results in cleavage at two sites Arg 145 - Ala 146 and 
Arg 180 - Val 181 [Thompson, 1990].
A putative promoter region is present 5' to the transcription mutation site in the DNA. 
This region contains distinct nucleotide changes in patients with haemophilia B Leyden,
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the condition where severe haemophilia B becomes mild after puberty [Reitsma et al,
1988].
As is the case for the factor VIII gene, further patients with partial and complete gene 
deletions have been described. As more have been described, the relationship between 
presence of factor IX inhibitor and deleted gene has been seen to be less strong than 
originally imagined.
CpG dinucleotides, which are relatively underrepresented in the factor IX molecule again 
appear to be an important mutation site. 18 mutations sites,involving CpG 
dinucleotides, in 45 distinct families, have been identified accounting for nearly half of 
the patients with haemophilia B associated with point mutation [Thompson, 1990].
Bottema et al [1990] describe a point mutation consisting of a T -> C transition at base 
31311 which results in a lie -> Thr transition. This was detected in 17% of 65 patients 
screened and was associated with a mild to moderate haemophilia B phenotype. 
Although these patients were thought to be unrelated, RFLP analysis showed that they 
all shared the same rare haplotype suggesting a common ancestor.
Unlike haemophilia A, where until very recently screening for point mutations has 
required a directed search strategy, often around known cleavage sites, the shorter length 
of the factor IX gene has enabled diagnosis of the molecular defects resulting in 
haemophilia B by direct sequencing of factor IX exons, plus intron-exon boundaries 
promoter and termination signal regions amplified by PCR [Green et al, 1989]. The 
techniques of direct detection of point mutations by mismatch analysis following 
chemical cleavage has also been shown to be a highly sensitive method which avoids the 
necessity of extensive DNA sequencing [Montandon et al, 1989].
These same methods can then be applied to earner detection and prenatal diagnosis. 
Montandon et al [1989] describe carrier detection in four females where the haemophilia 
B was an isolated event. One case was shown to be a true new mutation but the other 
three showed the molecular defect in the mother of the haemophiliac and in one case his 
sister demonstrating the applicability of these methods in families with no family history 
of haemophilia B.
V.4iii Von W illebrands Disease
The structural domains of the von Willebrands factor cDNA are described in the 
introduction. The complete exon and intron structure of the vWF gene has now been
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established by Mancuso et al [1989] and the approximate localisations for known vWF 
functional domains are now known. Exon 28 is the largest exon at 1.4kb and codes for 
the Ai and A2  domains which contain binding sites for platelet glycoprotein lb, heparin 
and collagen. Defects resulting in type IIA vWD have been localised to domain A2  and 
those resulting in type IIB vWD have been localised to domain Ai. Factor VIII binding 
localises to domain D' whilst the binding site for the platelet glycoprotein Ilb/IIIa 
complex is present at the 3' end of the gene and lies at amino acid 1744-7 [Ginsburg and 
Bowie, 1992].
Molecular studies in von Willebrands disease have been impeded because there is a 
pseudogene present in chromosome 22 which has 97% homology with the central region 
of the vWF gene on chromosome 12 from exon 23 to exon 34 [Mancuso et al, 1991]. 
Studies attempting to identify deletions or point mutations in this area are severely limited 
by this pseudogene.
The family presenting with an individual affected by type III vWD described in this 
thesis had results suggesting this severe vWD was due to a double dose of an autosomal 
dominant disorder. It is now apparent that this is a less common pattern for type III 
vWD than to have parents of the proband who are completely asymptomatic [Ginsburg 
and Bowie, 1992]. Nichols et al [1991] demonstrated an abnormality at the level of 
mRNA expression from both maternal and paternal alleles in one type III vWD pedigree. 
All offspring inheriting both aberrant alleles were affected with type III vWD whereas 
both parents and five heterozygous siblings were asymptomatic and had normal vWF 
plasma levels.
Type IIA vWD which is particularly associated with loss of higher molecular weight 
multimers has been shown by a combination of protein studies and molecular biology to 
fall into two aetiological groups. In the first group, a point mutation results in a failure 
of transport of the vWF multimers causing them to be retained in the endoplasmic 
reticulum. The larger multimers are retained to a greater degree [Lyons et al, 1992]. In 
the second group a variety of point mutations result in an increased susceptibility to 
proteolytic cleavage between residues Tyr-842 and Met 843 [Dent et al, 1990].
Type IIB vWD is characterised by an increase in binding between the vWF molecule and 
platelet glycoprotein lb. Since the binding site for Gplb has been localised to the Ai 
domain of the vWF gene seven specific single amino acid substitutions and one insertion 
have been identified in this area. Furthermore vWF fragments expressing these 
identified mutations have been associated with increased platelet binding [Ginsburg and 
Bowie, 1992].
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Mutations located within the N-terminal region of the vWF molecule interfere with the 
ability of the vWF molecule to bind FVIII. The identification of these mutations has 
helped to define a new variant of vWD associated with low levels of circulating factor 
VIII. This condition has caused much confusion in the past and has been described as 
autosomal haemophilia.
Gene deletion does not appear to be a major cause of vWD; only two partial gene 
deletions have been described since those identified by Shelton-Inloes et al [1987B] and 
Ngo et al [1988], one causing severe vWD [Peake et al, 1990A] and one causing a 
valiant type II vWD [Bernardi et al, 1990]. The fact that vWD is a heterozygous disease 
caused by a variety of point mutations in the majority of cases along with the known 
existence of a pseudogene makes a strategy for carrier detection and prenatal diagnosis 
difficult. The identification of a highly informative variable number tandem repeat 
(VNTR) in intron 40 [Peake et al, 1990B] will improve carrier detection rates in families 
which are not informative for RFLPs already identified.
As yet no molecular lesion has been identified as the cause of the most common type of 
vWD, type I which is associated with a functional decrease in all aspects of the vWF 
molecule along with normal multimer distribution. This generalised decrease in protein 
production may not be due to an intragenic lesion but may be due to a defective promoter 
or initiator of RNA transcription or to a sequence of DNA which terminates 
transcription.
The applications of molecular biology in these disorders are not limited to diagnosis. 
Already limited amounts of factor VIII have been manufactured using recombinant DNA 
technology and in the future this may be an important source of therapeutic material. 
Equally important, there is a great deal of interest in and research around the possibility 
of gene therapy: that is of replacing the faulty gene and thereby curing the genetic 
disorder [Lancet, 1990; Feigner and Rhodes, 1991]. This would offer tremendous 
hope for carriers of genetic disease although there are as yet many technical problems to 
be overcome.
Molecular genetics has already transformed the investigation and management of 
individuals with inherited bleeding disorders. Future developments are likely to lead 
ultimately to both prevention and cure: an exciting prospect.
V.5 ORGANISING A HAEMOPHILIA SERVICE: 
PRACTICAL IMPLICATIONS
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In the context of the haemophilias and von Willebrands disease, it is worth examining 
the practical implications of these changes. At present most haemophilia centres in the 
United Kingdom are run by haematologists. Haemophiliacs (and patients with von 
Willebrands disease) are registered at diagnosis and treatment instituted. It is usual to 
invite patients to attend a review clinic once or twice a year. Here they can discuss any 
treatment problems and also see the dentist, physiotherapist, orthopaedic surgeon or 
other specialist as appropriate. Genetic advice is usually given at diagnosis and then at 
these review clinics when requested. It is unlikely that this is adequate. In a survey 
published in 1986, Markova et al presented data from haemophiliacs and carriers from 
centres in four countries including the centre in Glasgow where this present work was 
carried out. Only 24% of the Scottish haemophiliacs said that they had received genetic 
counselling and only 78% had received information about the transmission of 
haemophilia. These figures compare poorly with the clinic in New York where 91% of 
haemophiliacs received genetic counselling and 100% had received information about 
disease transmission. This is not meant as an indictment of the hard pressed doctors 
currently running the haemophilia centre in Glasgow. Indeed it may well be that the 
Scottish haemophiliacs had received genetic counselling but did not recognise it as such 
since it took place during a routine clinic and did not involve a geneticist. However, the 
survey does highlight the lack of information felt by both haemophiliacs and carriers and 
would suggest that more time needs to be set aside for genetic counselling. A further 
problem with relaying information about genetic risks is that people's perception of the 
information may vary according to the context in which it is given and also information 
given to a couple who are then allowed to discuss this may have a different impact from 
information given to individuals [d'Ydewalle and Evers-Kiebooms, 1987]. This is very 
important in the context of haemophilia particularly if a couple present, seeking genetic 
counselling, when the woman is already pregnant and under pressure to make a 
decision. Interestingly, in the study by Markova et al [1986] in contrast to 44% of 
haemophiliacs, only 22% of carriers felt that haemophilia was no problem at all. Ten out 
of 37 sisters of haemophiliac men felt that there was a great degree of strain in the family 
caused by the disease. In this context, it is possible that the response of possible carriers 
of haemophilia to genetic counselling will vary depending on whether they present with 
their haemophiliac relative or not.
For the population at risk of inherited coagulation disorders, the benefits of improved 
diagnostic techniques can only be maximised by a combination of access to a molecular 
genetics laboratory where the appropriate tests are available along with support from
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haematology, obstetric and genetics departments. At a time when the financial efficiency 
of all departments is being questioned, establishing a service which involves a 
combination of expensive and relatively labour intensive laboratory methods and genetic 
counselling by highly trained personnel may not seem attractive to those who administer 
hospital budgets. Against this however the cost of treating haemophilia should be set 
out. Figures for 1990 for a small haemophilia centre in Yorkshire showed that 34 men 
with haemophilia A were given 1.1 million units of the NHS factor VIII concentrate at 
21p/unit and 150,000 units of Monoclate (factor VIII purified by monoclonal antibody) 
at 45p/unit. Added to this one must consider the costs of hospital attendance and 
admission, surgical treatment and other likely treatments. Clearly, not preventing 
haemophilia has financial implications over a lifetime.
The slant of this final chapter is very much aimed at families affected by haemophilia A 
and B rather than von Willebrand's disease where problems are rarely so severe. 
Nonetheless, because of this, families may not be offered genetic counselling and 
perhaps it should be borne in mind that they too may need support and advice prior to 
starting a family.
71
C H A PTER  VI- REFEREN CES
Addis T. Pathogenesis of hereditary haemophilia. J Pathol Bacteriol 1911; 15: 427-52.
Aggeler PM, White SG, Glendening MB, Page EW, Leake TB, Bates G. Plasma 
thromboplastin component deficiency (PTC deficiency): new disease resembling 
haemophilia. Proc Soc Exp Biol Med 1952; 79: 692-4.
Akhmeteli MA, Aledort LM, Alexaniants S et al. Methods for the detection of 
haemophilia carriers: a Memorandum. Bull World Health Organ 1977; 55: 675-702.
Anonymous. Genes and colour blindness. Lancet 1990; 335: 263-264.
Anonymous. Cystic fibrosis: Towards the ultimate therapy, slowly. Lancet 1990; 336: 
1224-1225.
Anson DS, Choo KH, Rees DJG et al. The gene structure of human anti-haemophilic 
factor IX. EMBO J 1984; 3: 1053-60.
Antonarakis SE, Waber PG, Kittur SD et al. Haemophilia A. Detection of Molecular 
Defects and of Carriers by DNA Analysis. N Engl J Med 1985A; 313: 842-8.
Antonarakis SE, Copeland KL, Carpenter RJ et al. Prenatal diagnosis of haemophilia A 
by factor VIII gene analysis. Lancet 1985B; i: 1408-9.
Antonarakis SE, Youssoufian H, Kazazian HH Jr. Molecular genetics of haemophilia A 
in man (factor VIII deficiency). Mol Biol Med 1987; 4: 81-94.
Arai M, Higuchi M, Antonarakis SE et al. Characterisation of a thrombin cleavage site 
mutation (ARG 1689 to CYS) in factor VIII gene in two unrelated patients with cross­
reacting material-positive haemophilia A. Blood 1990; 75: 384-9.
Bahnak BR, Lavergne J-M, Verweij CL et al. Carrier detection in severe (Type III) von 
Willebrand disease using two intragenic restrictive fragment length polymorphisms. 
Thromb Haemost 1988; 60: 178-81.
Ball J, Warnock LJ, Preston FE. Rapid assessment of haemophilia A carrier status by 
non-invasive techniques using the polymerase chain reaction. J Clin Pathol 1990; 43:
505-7.
72
Bennett B, Ratnoff OD. Detection of the carrier state for classic haemophilia. N Engl J 
Med 1973; 288: 342-5.
Bennett E, Dormandy K. Pool's cryoprecipitate and exhausted plasma in the treatment 
of von Willebrand disease and factor XI deficiency. Lancet 1966; ii: 731-2.
Bennett E, Huehns ER. Immunological differentiation of three types of haemophilia and 
identification of some female carriers. Lancet 1970; ii: 956-8.
Bernardi F, Del Senno L, Barbieri R et al. Gene deletion in an Italian haemophilia B 
subject. J Med Genet 1985; 22: 305-7.
Bernardi F, Marchetti G, Bertagnolo V, Faggioli L, del Senno L. Two Taq I RFLPs in 
the human von Willebrand factor gene. Nucl Acids Res 1987; 15: 1347
Bernardi F, Guerra S, Patracchini P et al. Von Willebrand disease investigated by two 
novel RFLPs. Br J Haematol 1988; 68: 243-248.
Bernardi F, Marchetti G, Guerra S et al. A de novo and heterozygous gene deletion 
causing a variant of von Willebrand disease. Blood 1990; 75: 677-83.
Berntorp E, Nilsson IM. Use of a high purity factor VIII concentrate (HEMATE P) in 
von Willebrands disease. Vox Sang 1989; 56: 212-7.
Biggs R, Douglas AS, MacFarlane RG et al. Christmas disease: a condition previously 
mistaken for haemophilia. B rM edJ 1952; 2: 1378-82.
Biggs R, Douglas AS. The thromboplastin generation test. J Clin Pathol 1953; 6: 23-9.
Biggs R. Haemophilia treatment in the United Kingdom from 1969 to 1974. Br J 
Haematol 1977; 35: 487-504.
Bloom AL. Inherited disorders of blood coagulation. In: Bloom AL, Thomas DP, eds. 
Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1981: 321-70.
Bloom AL. Inherited disorders of blood coagulation. In: Bloom AL, Thomas DP, eds. 
Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1987: 393-436.
73
Bloom AL, Giddings JC, Peake IR. The haemophilias. In: Poller L, ed. Recent 
advances in Blood Coagulation (4). Edinburgh: Churchill Livingstone, 1985: 91-116.
Brocket-Vriends AHJT, Briet E, Quadt R et al. Cartier detection of haemophilia B using 
an intragenic restriction fragment length polymorphism. Thromb Haemost 1985; 54:
506-9.
Brocker-Vriends AHJT, Briet E, Quadt R et al. Genotype assignment of haemophilia A 
by use of intragenic and extragenic restriction fragment length polymorphisms. Thromb 
Haemost 1987; 57: 131-6.
Camerino G, Grzeschik KH, Jaye M, De La Salle H, Tolstoshev P, Lecocq JP. 
Regional localisation on the human X chromosome and polymorphism of the coagulation 
factor IX gene (hemophilia B locus). Proc Natl Acad Sci USA 1984; 81: 498-502.
Camerino G, Oberle I, Daryna D, Mandel JL. A new MspI restriction fragment length 
polymorphism in the haemophilia B locus. Hum Genet 1985; 71: 79-81.
Canadian Collaborative CVS-Amniocentesis Clinical Trial Group. Multicentre 
randomised clinical trial of chorionic villus sampling and amniocentesis. Lancet 1989; i: 
1- 6 .
Collins CJ, Underdahl JP, Levene RB et al. Molecular cloning of the human gene for 
von Willebrand factor and identification of the transcription initiation site. Proc Natl 
Acad Sci USA 1987; 84: 4393-7.
Cooper JA. Oncogenes and anti-oncogenes. Cun* Opin Cell Biol 1990; 2: 285-295.
Craig I, Ross M, Edwards JH, Fraser N, Hall J. Detecting maternal cell contamination 
in prenatal diagnosis. Lancet 1989; i: 1074-5.
Dacie JV, Lewis SM. Practical Haematology (Sixth Edition). Edinburgh: Churchill 
Livingstone, 1984.
Darby SC, Rizza CR, Doll R, Spooner RJD, Stratton IM, Thakrar B. Incidence of 
AIDS and excess of mortality associated with HIV in haemophiliacs in the United 
Kingdom: report on behalf of the directors of haemophilia centres in the United 
Kingdom. BrM ed J 1989; 298: 1064-8.
74
Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage 
site directing the immunochemical detection of molecular abnormalities in type IIA von 
Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-10.
Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 
145: 1310-2.
Driscoll MC, Dispenzieri A, Tobias E, Miller CH, Aledort LM. A second BAM HI 
DNA polymorphism and haplotype association in the factor IX gene. Blood 1988; 72: 
61-5.
d'Ydewalle G, Evers-Kiebooms G. Experiments on genetic risk perception and decision 
making: explorative studies. Birth Defects Original Article Series 1987; 23: 209-25
Ewerhardt B, Ludwig M, Schwaab R, Schneppenheim R, Olek K. An EcoRI 
polymorphism in the human von Willebrand factor (vWF) gene. Nucl Acids Res 1989; 
17: 5416.
Eyster ME, Gill FM, Blatt PM, Hilgartner MW, Ballard JO, Kinney TR. Central 
nervous system bleeding in haemophiliacs. Blood 1978; 51: 1179-88.
Feinberg AP, Vogelstein B. A technique for radiolabelling DNA restriction 
endonuclease fragments to high specific activity. Analyt Biochem 1983; 132: 6-13.
Feigner PL, Rhodes G. Gene therapeutics. Nature 1991; 349: 351-352.
Filippi G, Mannucci PM, Coppola R, Farris A, Rinaldi A, Siniscalco M. Studies in 
haemophilia A in Sardinia bearing on the problems of multiple allelism carrier detection 
and differential mutation rate in the two sexes. Am J Hum Genet 1984; 36: 44-71.
Firshein SI, Hoyer LW, Lazarchick J et al. Prenatal diagnosis of classic hemophilia. N 
Engl J Med 1979; 300: 937-41.
Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non A non B hepatitis after 
transfusion of factor VIII in infrequently treated patients. Br Med J 1983; 287: 1754-7.
Giannelli F, Choo KH, Rees DJG, Boyd Y, Rizza CR, Brownlee GG. Gene deletions 
in patients with haemophilia B and anti-factor IX antibodies. Nature 1983; 303: 181-2.
75
Giannelli F, Anson DS, Choo KH et al. Characterisation and use of an intragenic 
polymorphism marker for detection of carriers of haemophilia B (factor IX deficiency). 
Lancet 1984; i: 239-41.
Ginsburg D, Handim RI, Bonthrom DT et al. Human von Willebrand factor (vWF): 
Isolation of complementary DNA (cDNA) Clones and chromosomal localisation. 
Science 1985; 228: 1401-6.
Ginsburg D, Bowie EJW. Molecular genetics of von Willebrand disease. Blood 1992; 
79: 2507-19.
Girma JP, Kalafatis M, Pietu G et al. Mapping of distinct von Willebrand factor 
domains interacting with platelet GPIb and GPIIb/HIa and with collagen using 
monoclonal antibodies. Blood 1986; 67: 1356-66.
Gitschier J, Wood WI, Goralka TM et al. Characterisation of the human factor VIII 
gene. Nature 1984; 312: 326-30.
Gitschier J, Drayna D, Tuddenham EGD, White RL, Lawn RM. Genetic mapping and 
diagnosis of haemophilia A achieved through a Bel I polymoiphism in the factor VIII 
gene. Nature 1985A; 314: 738-40.
Gitschier J, Wood WI, Tuddenham EGD et al. Detection and sequence of mutations in 
the factor VIII gene of haemophiliacs. Nature 1985B; 315: 427-30.
Gitschier J, Wood WI, Shuman MA, Lawn RM. Identification of a missense mutation 
in the factor VIII gene of a mild haemophiliac. Science 1986; 232: 1415-6.
Gitschier J, Kogan S, Levinson B, Tuddenham EGD. Mutations of factor VIII cleavage 
sites in hemophilia A. Blood 1988; 72: 1022-8.
Graham JB, Green PP, McGraw RA, Davis LM. Application of molecular genetics to 
prenatal diagnosis and carrier detection in the haemophilias: some limitations. Blood 
1985; 6 6 : 759-64.
Graham JB, Rizza CR, Chediak J et al. Carrier Detection in Haemophilia A: A 
cooperative international study. I. The carrier phenotype. Blood 1986; 67: 1554-9.
76
Green PM, Bentley DR, Mibashan RS, Nilsson IM, Giannelli F. Molecular pathology 
of haemophilia B. EMBO J 1989; 8 : 1067-72.
Haldane JBS, Smith CAB. A new estimate of the linkage between the genes for colour 
blindness and haemophilia in man. Ann Eugenics 1947; 14: 10-31.
Harper K, Winter RM, Pembrey ME, Hartley D, Davies KE, Tuddenham EGD. A 
clinically useful DNA probe closely linked to haemophilia A. Lancet 1984; ii: 6 -8 .
Hassan HJ, Orlando M, Leonardi A et al. Intragenic factor IX restriction site 
polymorphism in haemophilia B valiants. Blood 1985; 65: 441-3.
Hassan HJ, Leonardi A, Guerriero R et al. Haemophilia B with inhibitor molecular 
analysis of the subtotal deletion of the factor IX gene. Blood 1985; 6 6 : 728-30.
Hay CW, Robertson CA, Yong SL, Thompson AR, Growe GH, MacGillivray RTA. 
Use of a BAM HI polymorphism in the factor IX gene for the determination of 
haemophilia B carrier status. Blood 1986; 67: 1508-11.
Hay CRM, Preston FE, Triger DR, Underwood JCE. Progressive liver disease in 
haemophilia: an understated problem? Lancet 1985; i: 1495-8.
Hay J. Account of a remarkable haemorrhagic disposition existing in many individuals 
of the same family. N Engl J Med 1813; 2: 221.
Holmberg L, Nilsson IM. Von Willebrand Disease. Clin Haematol 1985; 14: 461-88.
Hoyer LW, Carta CA, Mahoney MJ. Detection of Haemophilia Carriers during 
pregnancy. Blood 1982; 60: 1407-10.
Hutton RA. Normal Haemostasis. In: Hoffbrand AV, Lewis SM, eds. Postgraduate 
Haematology. Oxford: Heinemann 1989: 560-97.
Iannuzzi MC, Konkle BA, Ginsburg D, Collins FS. Rsal RFLP in the human von 
Willebrand factor gene. Nucl Acids Res 1987; 14: 5909.
Inbal A, Handin RI. Two Taq I polymorphisms in the 5' region of the von Willebrand 
factor (vWF) gene. Nucl Acids Res 1989; 17: 10143.
77
Intrator S, Noel B, Lucotte G. Carrier testing strategy in haemophilia A using two 
polymorphic DNA probes of the factor VIII gene. Exp Haematol 1987; 15: 304-5.
Jackson LG, Wapner RJ. Risks of chorionic villus sampling. Clin Obstet Gynaecol 
1987; 1: 513-31.
Janco RL, Phillips JA, Orlando P, Davies KE, Old J, Antonarakis SE. Carrier testing 
strategy in haemophilia A. Lancet 1986; i: 148.
Janco RL, Phillips JA, Orlando P, Woodard MJ, Wion KL, Lawn RM. Detection of 
haemophilia A carriers using intragenic factor VIII:C DNA polymorphisms. Blood 
1987; 69: 1539-41.
Jeffreys AJ, Wilson V, Thein SL. Individual-specific "fingerprints" of human DNA. 
Nature 1985; 316: 76-9.
Jones P. Developments and problems in the management of haemophilia. Semin 
Haematol 1977; 14: 375-90.
Kan YW, Dozy AM. Antenatal diagnosis of sickle cell anaemia by DNA analysis of 
amniotic fluid cells. Lancet 1978; ii: 910.
Kazazian HH, Wong C, Youssoufian H, Scott AF, Phillips DG, Antonarakis SE. 
Haemophilia A resulting from de novo insertion of LU1D sequences represents a novel 
mechanism for mutation in man. Nature 1988; 332: 164-6.
Ken wrick S, Gitschier J. A contiguous 3-Mb physical map of Xq28 extending from the 
colourblindness locus to DXS 15. Am J Hum Genet 1989; 45: 873-882.
Kirkwood TBL, Rizza CR, Snape TJ, Rhymes IL, Austen DEG. Identification of 
Sources of inter-laboratory variation in factor VIII assay. Br J Haematol 1977; 37: 559- 
6 8 .
Klein HG, Aledort LM, Bouma BN, Hoyer LW, Zimmerman TS, DeMets DL. A co­
operative study for the detection of the earner state of classic haemophilia. N Engl J 
Med 1977; 296: 959-62.
Kobrinsky NL, Watson CM, Cheang MS, Bishop AJ. Improved haemophilia A carrier 
detection by DDAVP stimulation of factor VIII. J Pediatr 1984; 104: 718-24.
78
Kogan SC, Doherty M, Gitschier J. An improved method for prenatal diagnosis of 
genetic diseases by analysis of amplified DNA sequences. N Engl J Med 1987; 317: 
985-90.
Kogan S, Gitschier J. Mutations and a polymorphism in the factor VIII gene discovered 
by denaturing gradient gel electrophoresis. Proc Natl Acad Sci 1990; 87: 2092-6.
Kojima T, Tanimoto M, Kamiya T et al. Possible absence of common polymorphisms 
in coagulation factor IX gene in Japanese subjects. Blood 1987; 69: 344-52.
Konkle BA, Kim S, Iannuzzi MC, Alani R, Collins FS, Ginsburg D. SacI RFLP in the 
human von Willebrand factor gene. Nucl Acids Res 1987; 15: 6766.
Kurachi K, Chen SH. Human genes for factor IX and other vitamin K dependent blood 
proteins. Adv Exp Med Biol 1987; 214: 67-81.
Langdell RD, Wagner RH, Brinkhous KM. Effect of anti haemophiliac factor on one 
stage clotting tests. A presumptive test for haemophilia and a simple one stage anti 
haemophiliac factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
Lathrop GM, Lalouel JM. Easy calculations of lod scores and genetic risks on small 
computers. Am J Hum Genet 1984; 36: 460-465.
Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel 
containing antibodies. Analytical Biochemistry 1966; 15: 45-52.
Lavergne J-M, Bahnak BR, Verweij CL, Pannekoek H, Meyer D. A second Xbal 
polymorphic site within the human von Willebrand factor (vWF) gene. Nucl Acids Res 
1987; 15: 9099.
Lavergne J-M, Bahnak BR, Assouling Z et al. A Taq I polymorphism in the 5' region 
of the von Willebrand factor (vWF) gene. Nucl Acids Res 1988; 16: 2742.
Lavergne J-M, Laurian Y, Dudilleux A, Larrieu MJ, Bahnak BR, Meyer D. Carrier 
detection and prenatal diagnosis in 98 families of haemophilia B by linkage analysis and 
direct detection of mutations. Blood Coag Fibrinol 1991; 2: 293-301.
79
Lehesjoki AE, de la Chapell A, Rasi V. Haemophilia A: Two recombinations detected 
with probe Stl4. Lancet 1986; ii: 280.
Lehesjoki AE, Rasi V, de la Chapelle A. Haemophilia B: diagnostic value of RFLP 
analysis in 19 of the 20 known Finnish families. Clin Genet 1990; 38: 187-97.
Levinson B, Lehesjoki A-E, de la Chapelle A, Gitschier J. Molecular analysis of 
hemophilia A mutations in the Finnish population. Am J Hum Genet 1990; 46: 53-62.
Lillicrap DP, Liddell MB, Matthews RJ, Peake IR, Bloom AL. Comparison of 
phenotypic assessment and the use of two restriction fragment length polymorphisms in 
the diagnosis of carrier status in haemophilia B. Br J Haematol 1986; 67: 557-65.
Lindstedt M, Anvret M. An EcoRI polymorphism of the human von Willebrand factor 
cDNA (vWF). Nucl Acids Res 1989; 17: 2882.
Lindstedt M, Amvret M. An EcoRI polymorphism of the human von Willebrand factor 
cDNA. Nucl Acids Res 1989; 17: 6435.
Lubahn DB, Lord ST, Bosco J et al. Population genetics of coagulant factor IX: 
frequencies of two DNA polymorphisms in five ethnic groups. Am J Hum Genet 1987; 
40: 527-36.
Ludlam CA, Peake IR, Allen N, Davies BL, Furlong RA. Factor VIII and fibrinolytic 
response to deamino-8 -D arginine vasopressin in normal subjects and dissociate 
response in some patients with haemophilia and von Willebrand disease. Br J Haematol 
1980; 45:499-511.
Lynch DC, Zimmerman TS, Collins CJ et al. Molecular cloning of cDNA for human 
von Willebrand factor: authentication by a new method. Cell 1985; 41: 49-56.
Lyon MF. Sex chromation and gene action in the mammalian X-chromosome. Am J 
Hum Genet 1962; 14: 135-48.
Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport 
produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 
267: 4424-30.
80
Mackie IJ, Bull HA. Normal Haemostasis and its Regulation. Blood Reviews 1989; 3: 
237-50.
Macklin MT. Heredity in haemophilia. Am J Med Sci 1928; 175: 218-24.
McCurdy PR. Use of genetic linkage for the detection of female carriers of haemophilia. 
New Engl J Med 1971; 285: 218-9.
MacFarlane DG, Stibbe J, Kirkby EP, Zucker MB, Grant RA, McPherson J. A method 
for assaying von W illebrand factor (ristocetin co-factor). Thromb Diathesis 
Haemorrhagica 1975; 34: 306-8.
McFarlane RG. The enzyme cascade in the blood clotting mechanism and its function as 
a biochemical amplifier. Nature 1964; 202: 498-9.
McGraw RA, Davis LM, Lundblad RL, Stafford DW, Roberts HR. Structure and 
Function of factor DC: Defects in Haemophilia B. Clin Haematol 1985A; 14: 359-85.
McGraw RA, Davis LM, Noyes CM, Lundblad RL, Roberts HR, Graham JB, Stafford 
DW. Evidence for a prevalent dimorphism in the activation peptide of human 
coagulation factor DC. Proc Natl Acad Sci USA 1985B; 82: 2847-51.
Mancuso DJ, Tuley EA, Westfield LA et al. Structure of the gene for human von 
Willebrand factor. J Biol Chem 1989; 264: 19514-27.
Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and 
pseudogene: structural analysis and differentiation by polymerase chain reaction. 
Biochemistry 1991; 30: 253-69.
Marchetti G, Sacchi E, Patracchini P, Randi AM, Sampietro M, Bernardi F. Two 
additional Taq I RFLPs in von Willebrand factor gene (vWF) and pseudogene. Nucl 
Acids Res 1989; 17: 3329.
Markova I, Forbes CD, Aledort LM, Inwood M, Mandalaki T, Miller CH, Pittadaki J. 
A comparison of the availability and content of genetic counselling as perceived by 
haemophiliac men and carriers in the USA, Canada, Scotland and Greece. Am J Med 
Genet 1986; 24: 7-21.
81
Martini G, Tomiolo D, Vulliamy T et al. Structural analysis of the X-linked gene 
encoding human glucose 6  phosphate dehydrogenase. EMBO 1986; 5: 1849-55.
Merskey C, MacFarlane RG. The female earner of haemophilia. A clinical and 
laboratory study. Lancet 1951; i: 487-90.
Meyer D, Plas A, Allain JP, Sitar GM, Larrieu MJ. Problems in the detection of carriers 
of haemophilia A. J Clin Pathol 1975; 28: 690-5.
Mibashan RS, Rodeck CH, Thumpston JK et al. Plasma assay of fetal factor VIIIc and 
IX for prenatal diagnosis of haemophilia. Lancet 1979; i: 1309-11.
Millar DS, Green PJ, Zoll B, Kakkar VV, Cooper DN. Carrier detection in haemophilia 
A by direct analysis of factor VIII gene lesions. Hum Genet 1991; 87: 99-100.
Mitchell CD. Recessive oncogenes, antioncogenes and tumour suppression. Br Med 
Bull 1991; 47: 136-156.
Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations 
by mismatch analysis: application to haemophilia B. Nucl Acid Res 1989; 17: 3347-58.
Moodie P, Liddell MB, Peake IR, Bloom AL. Carrier detection in 50 haemophilia A 
kindred by means of three intragenic and two extragenic restriction fragment length 
polymorphisms. Br J Haematol 1988; 70: 77-84.
Morawitz P. Die Chemie der Blutgerinning. Ergebnisse der Physiologie 1904; 4: 307- 
416.
Mulligan LM, Grover HJ, Blanchette VS et al. Recombination between the factor VIII 
gene and the DXS52 locus gives the most probable genetic order as centromere-ffa(X)- 
DXS15-DXS52-F8C-telomere. Am J Med Genet 1987; 26: 757-60.
Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F. Detection of three novel 
mutations in two haemophilia A patients by rapid screening of whole essential region of 
factor VIII gene. Lancet 1991; 337: 635-9.
Neale GAM, Menarguez J, Kitchingman GR et al. Detection of minimal residual disease 
in T-cell acute lymphoblastic leukaemia using polymerase chain reaction predicts 
impending relapse. Blood 1991; 78: 739-747.
82
Ngo KY, Glotz VT, Koziol JA et al. Homozygous and heterozygous deletions of the 
von Willebrand factor gene in patients and earners of severe von Willebrand disease. 
Proc Natl Acad Sci USA 1988; 85: 2753-7.
Nichols WC, Lyons SE, Harrison JS, Cody RL, Ginsburg D. Severe von Willebrand 
disease due to a defect at the level of von Willebrand factor mRNA expression: detection 
by exonic PCR-restriction fragment length polymorphism. Proc Natl Acad Sci USA 
1991; 8 8 : 3857-61.
Nishino K, Lynch DC. A polymorphism of the human von Willebrand factor (vWF) 
gene with BamHI. Nucl Acids Res 1986; 14: 4697.
Oberle I, Drayna D, Camerino G, White R, Mandel J-L. The telomeric region of the 
human X chromosome long arm: presence of a highly polymorphic DNA marker and 
analysis of recombination frequency. Proc Natl Acad Sci USA, 1985A; 82: 2824-8.
Oberle I, Camerino G, Heilig R et al. Genetic screening for haemophilia A (classic 
haemophilia) with a polymorphic DNA probe. New Engl J Med 1985B; 312: 682-6.
Orstavik KH, Veltkamp JJ, Bertina RM, Hermans J. Detection of carriers of 
haemophilia B. Br J Haematol 1979; 42: 293-301.
Parekh VR, Mannucci PM, Ruggeri ZM. Immunological heterogeneity of haemophilia 
B: a multicentre study of 98 kindreds. Br J Haematol 1978, 40: 643-55.
Patek AJ, Taylor FHC. Hemophila II - Some properties of a substance obtained from 
normal human plasma effective in accelerating the coagulation of haemophiliac blood. J 
Clin Invest 1937; 16: 113-24.
Pattinson JK, Millar DS, McVey J et al. The molecular genetic analysis of haemophilia 
A: a directed search strategy for the detection of point mutations in the human factor VIII 
gene. Blood 1990; 76: 2242-8.
Peake IR, Bloom AL. Immunoradiometric assay of procoagulant factor VIII antigen in 
plasma and serum and its reduction in haemophilia. Preliminary studies on adult and 
fetal blood. Lancet 1978; i: 473-5.
83
Peake IR, Newcombe RG, Davies BL, Furlong RA, Ludlam CA, Bloom AL. Carrier 
detection in haemophilia A by immunological measurement of factor VIII related antigen 
(VIIIRAg) and factor VIII clotting antigen (VIIICAg). Br J Haematol 1981; 48: 651-60.
Peake IR, Furlong BL, Bloom AL. Carrier detection by direct gene analysis in a family 
with haemophilia B (factor IX deficiency). Lancet 1984; i: 242-3.
Peake IR, Lillicrap DP, Liddell MB, Matthews RJ, Bloom AL. Linked and intragenic 
probes for haemophilia A. Lancet 1985; ii: 1003-4.
Peake IR, Bloom AL. Recombination between genes and closely linked 
polymorphisms. Lancet 1986; i: 1335.
Peake IR, Liddell MB, Moodie P et al. Severe type III von Willebrand disease earned 
by a deletion of exon 42 of the von Willebrand factor gene: family studies that identify 
carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 
654-61.
Peake IR, Bowen D, Bignell P et al. Family studies and prenatal diagnosis in severe 
von Willebrand disease by polymerase chain reaction amplification of a variable number 
tandem repeat region of the von Willebrand factor gene. Blood 1990B; 76: 555-61.
Pecorara M, Casarino L, Mori PG et al. Haemophilia A: carrier detection and prenatal 
diagnosis by DNA analysis. Blood 1987; 70: 531-5.
Pool JG, Hershgold EJ, Pappenhagen A. High potency antihaemophiliac factor 
concentrate prepared from cryoglobin precipitate. Nature 1964; 203: 312.
Prentice CRM, Forbes CD, Monice S, McLaren AD. Calculation of predictive odds for 
possible carriers of haemophilia. Thromb Haemost 1975, 34: 740-7.
Quadt R, Verweij CL, de Vries CJM, Briet G, Pannekoek H. A polymorphic Xbal site 
within the human von Willebrand factor (vWF) gene identified by a vWF cDNA clone. 
Nucl Acids Res 1986; 14: 7139.
Quick AJ. The prothrombin in haemophilia and in obstructive jaundice. J Biol Chem 
1935, 109: 73-4.
84
Rapaport SI, Patch MJ, Moore FJ. Anti-haemophiliac globulin levels in earners of 
haemophilia A. J Clin Invest 1960; 39: 1619-25.
Reiner AP, Thompson AR. An Hhal polymorphism is present in factor IX genes of 
Asian subjects. Hum Genet 1990; 8 6 : 87-8.
Reitsma PH, Mandalaki T, Kaspar CK, Bertina RM, Briet E. The putative factor IX 
gene promoter in hemophilia B Leyden. Blood 1988; 72: 1074-6.
Rizza CR, Rhymes IL, Austen DEG, Kemoff PBA, Aroni SA. Detection of earners of 
haemophilia: a "blind" study. Br J Haematol 1975; 30: 447-56.
Rizza CR, Matthews JM. Clinical features of clotting factor deficiencies. In: Biggs R, 
Rizza CR (eds) Human Blood Coagulation, Haemostasis and Thrombosis (3rd edn), 
1984:119-69.
Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning 
and characterisation of two cDNA's coding for human von Willebrand factor. Proc Natl 
Acad Sci USA 1985; 82: 6394-8.
Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of beta-globin genomic 
sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 
230: 1350-4.
Sampietro M, Yang XY, Sacchi E, Mannucci PM, Bianchi A. Restriction of polymerase 
chain reaction products for carrier detection and prenatal diagnosis of haemophilia A: 
description of an internal control. Thromb Haemost 1990; 63: 527-8.
Schwaab R, Ludwig M, Kochnan L et al. Detection and characterisation of two 
missense mutations at a cleavage site in the factor VIII light chain. Thromb Res 1991; 
61: 225-34.
Shelton-Inloes BB, Broze GJ, Miletich JP, Sadler JE. Evolution of human von 
Willebrand factor: cDNA sequence polymorphisms, repeated domains and relationship 
to von Willebrand antigen II. Biochem Biophys Res Comm 1987A; 144: 657-65.
Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions 
correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 
1987B; 79: 1459-65.
85
Shima M, Ware J, Yoshiaka A, Fukui H, Fulcher C. An arginine to cysteine amino acid 
substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. 
Blood 1989; 74: 1612-7.
Simpson ME, Biggs R. The inheritance of Christmas factor. Br J Haematol 1962; 8 : 
191-203.
Southern EM. Detection of specific sequences among DNA fragments separated by gel 
electrophoresis. J Mol Biol 1975; 98: 503-17.
Spencer JW, Cox DN. Emotional response of pregnant women to chorionic villi 
sampling or amniocentesis. Am J Obstet Gynecol 1987; 157: 1155-60.
Stevens RF, Cuthbert AC, Perera PR et al. Liver disease in haemophiliacs: an 
overstated problem. Br J Haematol 1983; 55: 649-55.
Tantravahi V, Murty VVVS, Jhanwar SC et al. Physical mapping of the factor VIII gene 
proximal to two polymorphic DNA probes in human chromosome band Xq28: 
implications for factor VIII gene segregation analysis. Cytogenet Cell Genet 1986; 42: 
75-9.
Thompson AR. Radioimmunoassay of factor IX. In: Bloom AL, ed. Methods of 
Haematology (vol 5). The Haemophilias. Edinburgh: Churchill Livingstone, 1982: 
122-36.
Thompson AR. Factor IX and prothrombin in amniotic fluid and fetal plasma: 
Constraints on prenatal diagnosis of haemophilia B and evidence of proteolysis. Blood 
1984; 64: 867-74.
Thompson AR. Structure, function and molecular defects of factor IX. Blood 1986; 67: 
565-72.
Thompson AR. Molecular biology of the haemophilias. Prog Haemostas Thrombos 
1991; 10: 175-214.
Toole JJ, Knopf JL, Wozey JM et al. Molecular cloning of a cDNA encoding human 
antihaemophilic factor. Nature 1984; 312: 342-7.
86
Tuddenham EGD. Inherited bleeding disorders. In: Hoffbrand AV, Lewis SM, eds. 
Postgraduate Haematology. Oxford: Heinemann, 1989: 627-54.
Valderrama JAF, Matthews JM. The haemophiliac pseudotumour or haemophiliac 
subperiosteal haematoma. J Bone Joint Surg 1965, 47B: 256-65.
Van Dieijen G, Tans G, Rosing J, Henker HC. The role of phospholipid and factor 
V illa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
Van Dieijen G, Van Rijn JLML, Govers-Riemslag JWP, Hemker HC, Rosing J. 
Assembly of the intrinsic factor X activating complex - interactions between factor IXa, 
factor Villa and phospholipid. Thromb Haemost 1983; 53: 396-400.
Vehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 
337-42.
Verweij CL, de Vries CJM, Distel B et al. Construction of cDNA coding for human von 
Willebrand factor using antibody probes for colony-screening and mapping of the 
chromosomal gene. Nucl Acids Res 1985A; 13: 4699-4717.
Verweij CL, Hofker M, Briet E, Pannekoek H. RFLP for a human von Willebrands 
factor (vWF) cDNA clone pv WF1100. Nucl Acids Res 1985B; 13: 8289.
Verweij CL, Quadt R, Briet E, Dubbeldam K, van Ommen GB, Pannekoek H. Genetic 
linkage of two intragenic restriction fragment length polymorphisms with von 
Willebrand's disease type IIA. J Clin Invest 1988; 81: 1116-21.
Vidaud M, Chabret C, Gazengel C, Grunebaum L, Cazenave JP, Goossens M. A de
novo intragenic deletion of the potential EGF domain of the factor IX gene in a family
with severe haemophilia B. Blood 1986; 6 8 : 961-3.
Von Willebrand EA. Hereditare Pseudohemofili. Finska Lak-Sallsk Handl 1926; 6 8 : 
87-112.
Weatherall DJ. The new genetics and clinical practice. Oxford: Oxford University 
Press, 1985.
White GC, Matthews TJ, Weinhold KJ et al. Seroconversion associated with heat- 
treated factor VIII concentrate. Lancet 1986; i: 611-2.
87
Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in haemophilia B 
using two further intragenic restriction fragment length polymorphisms. Nucl Acids Res 
1984; 12: 8861-72.
Winter RM, Harper K, Goldman E et al. First himester prenatal diagnosis and detection 
of earners of haemophilia A using the linked DNA probe DX13. Br Med J 1985; 291: 
765-9.
Wintrobe MM. Hematology, The Blossoming of a Science: A Story of Inspiration and 
Effort. Philadelphia: Lea and Febiger, 1985.
Wood W, Capon DJ, Simonsen CC et al. Expression of active human factor VIII from 
recombinant DNA clones. Nature 1984; 312: 330-6.
Wright IS. The nomenclature of blood clotting factors. Thromb Haemost 1962; 7: 381- 
8 .
Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of 
the gene for human factor IX (antihaemophilic factor B). Biochemistry 1985; 24: 3736- 
50.
Youssoufian H, Kazazian HH, Phillips DG et al. Recurrent mutations in haemophilia A 
give evidence for CpG mutation hotspots. Nature 1986; 324: 380-2.
Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic 
haemophilia (factor VIII deficiency) and von Willebrands disease. J Clin Invest 1971; 
50: 244-54.
88
CHAPTER VII - APPENDICES
VH .l APPENDIX I Haemophilia A Results






Stl4 FV inc vWF:Ag
[kb] [iu/dl] [iu/dl]
Pedigree 2218
1 1 [0.9] [2 .8 ] [2 ]
1 2 [1.2/0.9] [2 .8 /2 .8 ] [3/7]
1 1 2 0.9 2 . 8 7
113 1.2/0.9 5/5 2 .8 /2 . 8 2/7 190 42
115 1.2/0.9 5/5 2 .8 /2 . 8 2/7
117 1.2/0.9 5/5 2 .8 /2 . 8 2/3 36 43
118 0.9 2 . 8 3
119 0.9 2 . 8 3
1 1 1 0 [0.9] [5.8]
1 1 1 1 0.9/0.9 2 .8 /2 . 8 2/3
III1 0.9 5 2 . 8 2
III2 0.9 5 2 . 8 2
III3 1 . 2 5 2 . 8 7 < 1
III4 1.2/0.9 2 .8 /2 . 8 7/7 130 1 0 0
III5 0.9/0.9 2 .8 /2 . 8 2/7 140 52
III6 1.2/0.9 2 .8 /2 . 8 7/7 80 125
III7 1 . 2 5 2 . 8 7 < 1
III8 0.9/0.9 5.8/2 . 8 2/3 82 50
III9 0.9 5 2 . 8 2
III10 1 . 2 5 2 . 8 3 2
III11 1.2/0.9 2 .8 /2 . 8 3/3
III12 1 . 2 5 2 . 8 3 < 1


















5.8/2 . 8  
5.8/2 . 8
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Individual F8A F8B DX13
[kb] [kb] [kb]

























1 1 [1 .2 ] [5] [2 .8 ] [8 ]
III [0.9] [5] [5.8] [2 ]
1 1 2 1 .2 / 1 . 2 20/5 5.8/2 . 8 3/8
113 [1 .2 ] [2 0 ] [5.8] [3]
114 [1 .2 / 1 .2 ] [20/5] [5.8/2.8 ] [3/8]
115 1 . 2 2 0 5.8 3
116 [0.9] [2 .8 ] [6 ]
117 1 .2 / 1 . 2 20/5 5.8/2 . 8 3/8
III1 0.9 5 2 . 8
III2 1 .2 /0 .9 20/5 5.8/5 . 8 2/3
III3 [1 .2 ] [2 .8 ]
III4 1 .2 / 1 . 2 2 0 / 2 0 5.8/5 . 8 3/3
III5 1 . 2 2 . 8 8
III6 1 . 2 2 0 5.8 3
III7 1 .2 / 1 . 2 20/5 5.8/2 . 8 3/8
III8 1 . 2 2 . 8
III9 0.9 2 . 8
III10 1 .2 / 1 . 2 2 0 / 2 0 5.8/5 . 8 3/3
III11 1 . 2 2 . 8 8
III12 1.2/0.9 20/5 5.8/2.8 3/6
III14 1.2/0.9 5/5 2 .8 /2 . 8 6 / 8
IV1 0.9 5 5.8 3
62 140
90
Individual F8A F8B DX13 Stl4 FVIIIc vWF 'J
[kb] [kb] [kb] [kb] [iu/dl] [iu/(
edigree 7399
IV2 1.2/0.9 20/5 5.8/2.8 3/7 35 72
IV3 1.2 5.8 3 < 1
IV5 1.2 5.8
IV6 1.2/1.2 20/20 5.8/2.8 37 121
IV7 1.2 5.8 3 < 1
IV8 1.2 5.8 3
IV9 1.2/1.2 20/20 5.8/5.8 3/3
IV10 1.2/1.2 20/5 5.8/2.8 3/8
IV11 1.2/1.2 20/5 5.8/2.8 3/8
IV12 1.2 20 5.8 3
IV13 1.2/1.2 20/5 5.8/2.8 56 105
IV14 1.2 20 5.8 < 1
VI 1.2/0.9 20/5 5.8/5.8 3/3 42 84
Pedigree 7402
1 2 [1.2/0.9] [5/5] [5.8/2.8 ] [2/7]
III 0.9 5 5.8 2
1 1 2 1 . 2 5 2 . 8 7
114 1.2/0.9 5/5 5.8/2 . 8 2/7
116 1 .2 /0 .9 5/5
117 [0.9] [5] [5.8] [3]
118 1 .2 / 1 . 2 20/5 2 .8 /2 . 8 5/7
III3 1 . 2
III4 1 . 2
III9 1.2/0.9 20/5 5.8/2 . 8 3/5
III11 0.9 5.8
III 12 1.2/0.9 20/5 5.8/2 . 8 3/5
III 13 0.9 5.8 8
III 14 1 .2 /0 .9 5/5 5.8/2 . 8 3/7
III15 1 . 2 5 2 . 8 5
III16 1 . 2 5 2 . 8 5
m i7 1 . 2 2 0 2 . 8 5
III 18 1 .2 /0 .9 5/5 5.8/2 . 8 3/7
IV4 1 . 2 2 . 8
IV 6 1 . 2 5 2 . 8 7
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Individual F8A F8B DX13 Stl4




11 [0.9] [5] [2.8] [8]
12 0.9/0.9 5/5 5.8/2.8 3/5
III [0.9] [5]
112 0.9 5 5.8 5
113 0.9 5.8 5
114 0.9/0.9 5/5 5.8/2.8 5/8
115 1.2 5.8 2
116 0.9/0.9 5/5 2.8/2.8 3/8
III1 0.9/0.9 5.8/5.8 5/5
III2 0.9 5 5.8 5
III3 0.9 5 2.8 8
III4 0.9 5 2.8 3 < 1
’edigree 7405
III 0.9 2.8 5
112 0.9/0.9 5/5 5.8/2.8 2/3 28 44
113 [1.2] [5] [5.8] [7]
114 [0.9/0.9] 5/5 [5.8/2.8] [2/3]
III2 0.9 5 2.8 3 20
III3 0.9 5 2.8 3 10
III4 0.9/0.9 5.8/2.8 2/5 130 115
III6 0.9/0.9 5.8/2.8 2/5 250* 185*
III8 0.9/0.9 5.8/2.8 2/7 180 165
III9 1.2/0.9 5.8/2.8 3/7 180 82
III10 1.2 2.8
m il 1.2/0.9 5/5 5.8/2.8 3/7 115 120
III12 0.9 2.8 6
m i3 1.2/0.9 5/5 5.8/2.8 3/7 48 48
IV1 0.9/0.9 5.8/2.8 2/7 180 180
IV2 0.9 5.8 2
IV4 0.9 5 2.8 3 11
IV6 1.2/0.9 2.8/2.8 3/6 130 100
IV7 0.9 5 2.8 3 6
IV8 0.9/0.9 2.8/2.8 3/6 74 175
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Individual F8A F8B DX13 Stl4 FVIIIc
[kb] [kb] [kb] [kb] [iu/dl]
Pedigree 7406
12 1.2/0.9 5/5 5.8/2.8 7/7 170
III 1.2 5 2.8 7 64
112 0.9/0.9 5.8/2.8 3/7
114 1.2/0.9 5.8/2.8 7/7 40
115 1.2 5 2.8 7 30
III1 1.2/0.9 5/5 5.8/2.8 3/7






11 [0.9] [5] [5.8] [3]
12 0.9/0.9 5/5 5.8/2.8 3/8
112 0.9/0.9 5/5 5.8/2.8 3/8 62 41
113 0.9 2.8 5
114 0.9/0.9 5/5 5.8/5.8 3/3 19 66
115 0.9 5 5.8 3 < 1
116 0.9/0.9 5.8/2.8 7/8
117 0.9 2.8
118 0.9/0.9 5/5 5.8/5.8 3/3
119 1.2 2.8
1110 0.9/0.9 5/5 5.8/5.8 3/3
1111 0.9 5.8 8
1112 0.9/0.9 5/5 5.8/2.8 3/8
1113 1.2 2.8 8
1114 0.9/0.9 5/5 5.8/5.8 3/3 41 50
III3 0.9 5.8
III5 0.9 5 2.8 8
III7 1.2/0.9 5.8/2.8 3/5
III8 0.9/0.9 5.8/5.8 3/7 170 42
III9 56 52
III10 50 57




Individual F8A F8B DX13 Stl4 FVIIIc vWF:Ag
[kb] [kb] [kb] [kb] [iu/dl] [iu/dl]
Pedigree 7407
III14 1.2/0.9 5.8/2.8 68 66
III15 1.2/0.9 5.8/2.8
III16 1.2/0.9 5.8/2.8
III17 0.9 5 3
III18 0.9 5 5.8 3
III 19 0.9 5 2.8 8
III20 0.9/0.9 5.8/2.8 8/8
III21 0.9/0.9 5.8/2.8 8/8
III22 1.2/0.9 5.8/2.8 3/8 68 46
Pedigree 7408
11 [0.9] [5] [5.8] [7]
12 0.9/0.9 5/5 2.8/2.8 2/9 50 84
III 0.9 5.8 1
112 0.9/0.9 5/5 5.8/2.8 2/7
114 0.9/0.9 5/5 5.8/2.8 2/7 90 88
115 0.9 5 2.8 2 4
116 0.9/0.9 2.8/2.8 5/7
117 0.9 5 2.8 2
III1 0.9/0.9 5.8/5.8 1/7 90 65
III2 0.9 5 5.8 7
III3 0.9 5 5.8
III4 0.9 5 2.8 2
III5 0.9/0.9 2.8/2.8 33 43
Pedigree 7409
11 0.9 2.8 8
12 0.9/0.9 2.8/2.8 3/8 100 100
III 0.9 2.8 3 1
112 0.9/0.9 2.8/2.8 3/8
113 0.9 2.8
94
Individual F8A F8B DX13 Stl4 FVIIIc vWF:^
[kb] [kb] [kb] [kb] [iu/dl] [iu/c
Pedigree 7410
III 0.9 5 2.8 2 10
112 1.2/0.9 2.8/2.8 7/9
113 1.2 2.8 3
114 0.9/0.9 5/5 5.8/2.8 2/5 130 120
115 0.9 2.8 9
116 0.9/0.9 5.8/2.8 2/5 110 120
117 0.9 2.8 6
118 0.9/0.9 5.8/2.8 2/5 66 55
119 1.2 2.8 3
1110 0.9/0.9 5.8/2.8 2/5 60 86
mi 0.9 5.8 3
1112 0.9/0.9 5/5 5.8/2.8 2/5 56 50
mi 0.9 5.8 3
III2 1.2/0.9 20/5 2.8/2.8 2/7 130 120
III3 0.9 5.8
III4 1.2/0.9 20/5 2.8/2.8 2/7 64 74
III5 0.9 2.8 37
III7 0.9/0.9 2.8/2.8 2/9 27 72
III8 0.9/0.9 5.8/2.8 100 100
III9 1.2/0.9 5.8/2.8 3/5 110 100
III10 1.2/0.9 5.8/2.8 3/5 100 60
III11 0.9 5 2.8 2 50
III 12 0.9 5 5.8 5
IV1 0.9 2.8 7
IV2 1.2 2.8 7
IV3 1.2/0.9 5.8/2.8 140 72
Pedigree 7411
11 [1.2] [5.8] [6]
12 [0.9/0.9] [5.8/2.8] [6/7]
III [0.9] [2.8] [2]
112 1.2/0.9 5.8/5.8 6/7
113 0.9 2.8 2
114 1.2/0.9 5/5 5.8/5.8 6/7
116 1.2/0.9 5.8/2.8 6/6
95
Individual F8A F8B DX13 Stl4 FVIIIc vWF:Ag
[kb] [kb] [kb] [kb] [iu/dl] [iu/dl]
Pedigree 7411
1111 0.9 5.8 7
1113 0.9/0.9 5.8/2.8 2/7
1114 1.2/0.9 5.8/2.8
1115 0.9 5 5.8 7
III7 0.9/0.9 5.8/2.8 2/7 77 137
ni8 0.9 5 5.8 7
HI9 1.2/0.9 5.8/2.8 2/6
Pedigree 7412
11 1.2 20 2.8
12 5.8/2.8
112 1.2/1.2 20/20 2.8/2.8 3/5 54 85
Pedigree 7413
111 1.2 5 2.8 2 1
112 0.9/0.9 5.8/5.8 2/5
1112 1.2/0.9 5/5 5.8/2.8 2/2
1113 1.2/0.9 5/5 5.8/2.8 2/5 56 76
1116 1.2/0.9 5.8/2.8 94 220
1117 0.9/0.9
IV1 1.2 5 2.8 2 2
* =  SAMPLES TAKEN WHEN WOMEN WERE PREGNANT 
[ ] =  RESULTS DEDUCED FROM RELATIVES' RESULTS
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1 1 2 1 . 8
114 1.8/1.3
116 1.8/1.3
118 1 . 8
119 [1.3/1.3]
1 1 1 1 1.3
1 1 1 2 1 . 8



























Individual F9(VIII)/Taq I F9(VIII)/Xmn I F9(XIII)/Dde I F9c
(kb) (kb) (kb) (iu/dl)
Pedigree 2377
1 1 2 1.8/1.3 11.5/11.5 1.7/1.7
119 1.8/1.3 11.5/11.5 1.7/1.7
III2 1 .8 / 1 .3 11.5/6.5 1.7/1.7 106
III7 1.3
III8 1.3/1.3 11.5/11.5 1.7/1.7
III13 1.3/1.3 11.5/11.5 1.7/1.7
IV1 1.3 4
IV2 1.8/1.3 11.5/11.5 1 2 0
IV3 1.3 6
IV5 1.3/1.3 11.5/11.5 80
IV6 1.3
IV7 1.3 11.5 6
IV 8 1.3
V I 1.3 5
Pedigree 3569
III 1 . 8
1 1 2 1.3/1.3 11.5/6.5 1.7/1.7
114 1.3/1.3 11.5/6.5
III1 1.3




IV1 1 . 8
IV2 1.3/1.3 11.5/11.5
IV3 1 .8 / 1 .3 11.5/11.5
IV4 1.3 11.5 1.7
Pedigree 4542




1117 1.8/1.8 11.5/11.5 1.75/1.7
98
Individual F9(VIII)/Taq I F9(VIII)/Xmn I F9(XIII)/Dde I F9c
(kb) (kb) (kb) (iu/dl)
Pedigree 4542
III9 1 .8 / 1 .3 11.5/6.5 1.75/1.7
III10 1 .8 / 1 .3 11.5/6.5 1.75/1.7
IV2 1 . 8 11.5 < 1
IVIO 1 .8 / 1 . 8 11.5/11.5 1.75/1.7
IV11 1 . 8 11.5 1.75 < 1
IV12 1 . 8
IV13 1 .8 / 1 . 8
VI 1.75/1.7
V2 1 . 8 < 1
V3 1 .8 / 1 . 8 11.5/11.5 1.75/1.7
Pedigree 4549
1 1 1.3 11.5
1 2 1.3/1.3 11.5/6.5 1.7/1.7 8 8
III 1.3
1 1 2 1.3 6.5 1.7
114 1.3/1.3 11.5/6.5 1.75/1.7 58
116 1.3/1.3 6.5/6.5 1.75/1.7 90
III1 1.8/1.3 11.5/6.5 1.7/1.7 82
III2 1.3/1.3
III4 1.3 1 0
III5 1.8/1.3 11.5/6.5 1.75/1.7 52
III6 1.3/1.3 11.5/11.5 90
III7 1.3 6.5
Pedigree 4551
1 1 [1 .8 ] [11.5] [1.7]
1 2 1 .8 / 1 . 8 11.5/11.5 1.7/1.7
1 1 2 1.8/1.3 11.5/11.5 1.7/1.7
113 1.3 6.5 1.75
114 1 .8 / 1 . 8 11.5/11.5 1.7/1.7
115 1.8/1.3
III1 1 . 8 11.5
III2 1 . 8 11.5
99
Individual F9(VIII)/Taq I F9(VIII)/Xmn I F9(XIII)/Dde I F9c
(kb) (kb) (kb) (iu/dl)
Pedigree 4551
1113 1.8/1.3 11.5/6.5 1.75/1.7
1114 1.8 11.5
1115 1.8 11.5 19
Pedigree 4555
114 1.3/1.3 11.5/6.5 1.7/1.7
n i4 1.3 11.5 1.7 5
III6 1.8/1.3 11.5/11.5 1.7/1.7
IV1 1.3
IV3 1.3 8
IV4 1.8/1.3 11.5/6.5 1.7/1.7 50




112 1.8/1.3 11.5/11.5 1.75/1.7
113 1.8






III6 1 . 8 11.5 < 1
IV1 1 . 8 11.5
IV2 1.8/1.3 11.5/6.5 1.7/1.7 40
IV3 1 . 8 11.5 1.7 < 1
IV7 1.8/1.3 11.5/11.5 1.7/1.7




Individual F9(VIII)/Taq I F9(VIII)/Xmn I F9(XIII)/Dde I F9c
(kb) (kb) (kb) (iu/dl)
Pedigree 5215 
12 1.8/1.3 11.5/6.5 1.7/1.7
111 1.8 11.5 < 1
112 1.8 11.5 < 1
114 1.3/1.3 11.5/6.5 50-76
Pedigree 5292 
m i  1.8 11.5 1.7
IV2 1.7
IV3 1.8/1 . 8  11.5/11.5 1.75/1.7
V2 1.7/1.7
V4 1.7/1.7
□ =  RESULTS DEDUCED FROM RELATIVES' RESULTS
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vn.3 APPENDIX HI Von WiUebrands Disease results
Individual pvWFllOO Bleeding Time FVIII: C vWF:Ag vWF(Ricof)
RFLP (kb) (mins) (iu/dl) (iu/dl) (iu/dl) \
Pedigree 7512
114 > 2 0  49 44 16
116 9/7.4






IV1 9/7.4 9 48 35 18
IV2 7.4/7.4
IV3 7.4/7.4
IV4 9/7.4 15 40 21 17
IV 6  9
Pedigree 7513
III3 9/7.4 15
IV1 9/7.4 9 100 82 8 8








III1 15 28 27 20
m 2  4 100 90 104
Pedigree 7515
111 9/7.4 9 100 70 41
112 9/7.4
1111 9/7.4 12 37 62 72
1112 4 100 90 104
102
Individual pvWFllOO Bleeding Time FVIII:C vWF:Ag vWF(Ricof) 
RFLP (kb) (mins) (iu/dl) (iu/dl) (iu/dl)
Pedigree 7516
114 15/9/7.4 > 20  44 15 21
III4 7.4/7.4 19 28 26 11
Pedigree 7517
11 9/7.4 19 30 35 14
12 9/7.4 17 32 20 25
111 9/9 > 2 0  2 12 > 1 0
112 9/7.4 14 48 18 28
113 7.4/7.4 5 115 72 6 6
Pedigree 7518
12 9/9
111 9/9 >  15 58 37 40
Pedigree 7519
112 9/9 > 3 0  44 20 22
III12 9/9 11 65 30 40
Pedigree 7520
112 9/9
III1 9/7.4 >  15 30 25 9
Pedigree 7521
112 9/7.4 > 20  52 92 10
III1 9/7.4 > 20  36 10
Pedigree 7522
116 9/7.4
III6  15/9/9 12 28 50
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